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1 INTRODUCTION  
1.1 Innate and adaptive immunity 
Nature developed the human immune system in order to protect our body’s integrity from 
the permanent challenge of invading microorganisms and generation of cancer cells by 
establishing mechanisms of host defense to eliminate infectious pathogens and tumor 
cells. The immune system can be conceptually differentiated in innate and adaptive (or 
acquired) immunity, which are intertwined by a multitude of interactions necessary to 
cooperatively eliminate pathogens and neoplasms. 
 
The innate immune system dates back very far in phylogenetic terms. This system acts 
rapidly as the frontline of defense during infections. The cell types involved are capable 
of phagocytosis, such as dendritic cells and macrophages, as well as detection of 
invading microorganisms. Subsequent goals are to prevent the spread of the infection 
and to induce an inflammatory response against it on a systemic level. The innate 
immune system is not a single entity, but rather an interplay of multiple differentiated 
subsystems. For example, the mucosa and the skin are functional barriers by producing 
antimicrobial peptides and mucinous proteins seeking to limit the invasion of pathogens. 
Another subsystem is represented by the production of acute phase proteins and 
complement factors that enable opsonization followed by lytic destruction of pathogens. 
In contrast to original assumptions, the innate immune response is not utterly unspecific 
as a limited set of genetically encoded pattern recognition receptors (PRR) allow the 
discrimination between self and foreign. PRRs recognize evolutionary conserved 
structures of microorganisms that are usually not present in vertebrates, so called 
pathogen-associated molecular patterns (PAMP). An important connection to the 
adaptive immune system is the production of chemokines to guide leukocytes to the site 
of infection. Further links include the processing as well as the subsequent presentation 
of antigens to adaptive immune cells like T and B cells using the major histocompatibility 
(MHC) protein family (Iwasaki and Medzhitov 2010). 
 
The adaptive immune system on the other hand makes use of a giant repertoire of 
antigen-specific receptors that is generated by somatic recombination of genes in T and 
B cells, producing T and B cell receptors that are expressed on the cell surface. This 
accounts for its high specificity and enables effective complete elimination of pathogens. 
At first however, these particular populations of lymphocytes need to replicate in a 
2 Introduction 
mechanism called clonal expansion, which explains why this system acts rather slowly. 
Another hallmark of the adaptive immune system is the generation of immunological 
memory, which enables long-lasting immunity for recurrent infections.  
 
However, both of these systems do not function in perfection. Endogenous molecules 
released after tissue damage or cell necrosis can for example also stimulate the innate 
immune system through PRRs and the specificities of T and B cells are not explicitly 
limited to foreign structures. For these potentially harmful situations, nature has evolved 
mechanisms of immunological tolerance. Nevertheless, this links both parts of the 
immune system to the pathogenesis of chronic autoimmune and inflammatory diseases.  
 
1.2 Immunological tolerance 
During the end of the 19th century, Paul Ehrlich postulated an immunological principle 
called horror autotoxicus (Silverstein 2001). He argued that the body’s immune system 
could only respond to foreign (or non-self-) structures – a reaction to self would be 
impossible as it would lead to a destruction of the host. Since the discovery of 
autoimmune diseases, we know that self-antigens are pivotal in their pathogenesis and 
therefore possible targets of the body’s immune system. In order to limit these harmful 
immune responses, nature has evolved three major mechanisms to provide the vital 
function of immunological tolerance.  
 
1.2.1 Central tolerance 
Central tolerance is a mechanism provided by the thymus, the site of T cell generation. 
Lymphoid progenitor cells arise from hematopoietic stem cells, populate the thymus and 
expand locally as immature thymocytes. In a first step called positive selection, 
thymocytes are tested for their capability to interact with the MHC class I or II complex, 
which requires a functional T cell receptor (TCR). For this purpose, thymocytes interact 
with cortical thymic epithelial cells (cTEC) in the cortex of the thymus. The ability to 
interact results in a survival signal for the thymocyte to promote its further development. 
In a second step called negative selection, the positively selected thymocytes migrate to 
the medulla of the thymus to interact with medullary thymic epithelial cells (mTEC) and 
thymic dendritic cells (tDC). mTEC have the potential to present a large variety of self-
antigens on the MHC class I for CD8+ thymocytes. In contrast, tDC phagocytose mTEC 
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and subsequently present antigens on the MHC class II for CD4+ thymocytes. 
Thymocytes strongly recognizing self-antigen will receive signals to undergo apoptosis 
in order to prevent later development of autoimmunity. Although approximately 98% of 
thymocytes do not survive positive and negative selection, a considerable amount of self-
reactive T cells is released into the blood stream as the selection of the thymus is not 
perfect and therefore considered leaky (Anderson, Venanzi et al. 2002). 
 
1.2.2 Peripheral tolerance 
To understand the concept of peripheral tolerance, we first need to recapitulate the basic 
steps of an immune response, for which the collaboration of innate and adaptive 
immunity is a necessity. This key process takes place in antigen-presenting cells (APC), 
that are capable of processing and presenting antigens on their cell surface to other 
immune cells. The APC with the highest grade of specialization for this task is the 
dendritic cell (DC). Its characteristic morphology allows efficient cell contacts through 
multiple branch-like protrusions on the cell surface, for which it received its name. DCs 
are present throughout almost every tissue in the body and are continuously sampling 
their surroundings through phagocytosis. Subsequently, the antigen uptake from 
pathogens, necrotic cells or immune complexes will be processed and presented using 
the major histocompatibility complex (MHC) molecules.  
 
Figure 1.1: Basic illustration of dendritic cell costimulation of T cells 
[The illustration is based on a review by Iwasaki and Medzhitov 2010.] 
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An important feature of DCs is their innate sensing of danger signals through PRRs, 
which activates them in a process called maturation by inducing the expression of 
costimulatory molecules, in particular CD80 and CD86. The current state of a DC, either 
immature (i.e. inactive) or mature (i.e. active), during antigen presentation and 
recognition is decisive. On the one hand, an immature DC interacting with a T cell 
recognizing its antigen will induce peripheral tolerance by rendering this T cell anergic, 
i.e. unable of clonal expansion. On the other hand, a mature DC will induce an effective 
immune response by signaling this T cell to expand. Therefore, an adaptive immune 
response requires two specific steps: (1) a danger signal inducing maturation of the DC, 
and (2) a T cell detecting its cognate antigen on the cell surface of a mature DC. An 
illustration of the process of costimulation is provided in Figure 1.1. 
 
As in the steady state of the immune system PAMPs are usually absent, DC maturation 
does not occur and self-reactive T cells are not activated, thereby providing a mechanism 
of peripheral tolerance. However, endogenous danger signals, e.g. DNA from dying cells 
as a danger-associated molecular pattern (DAMP), can also induce DC maturation.  
 
1.2.3 Dominant tolerance 
As central and peripheral tolerance significantly reduce but do not exclude self-reactive 
immune responses, an additional level of control in the form of dominant tolerance has 
evolved. A distinct CD4+ T helper cell lineage termed Foxp3+-regulatory T cells (TReg) can 
potently suppress immune responses of effector T cells (TEff). These cells are best 
characterized by constitutive expression of the transcription factor Foxp3, which is the 
master regulator of TReg and controls the expression of proteins that contribute to their 
function. During negative selection in the thymus, TReg survive in a specialized niche with 
a T cell receptor avidity that is thought to lie in between the recognition of foreign and 
self-antigen. After their initial identification in 1995 (Sakaguchi, Sakaguchi et al. 1995), it 
was shown that a deficiency in Foxp3 in mice leads to a complete deficiency of the TReg 
cell lineage and causes fatal forms of autoimmune disorders (Fontenot, Gavin et al. 
2003). The IPEX-Syndrome (Immune Dysregulation, Polyendocrinopathy, Enteropathy, 
X-linked) represents a rare disease with multi-organ autoimmunity in humans based on 
a mutation of the Foxp3 gene, provoking failure of dominant tolerance. 
 
Introduction 5 
 
 
1.3 Regulatory T cell function 
Regulatory T cells are guardians of our body’s immunological integrity. Preventing 
autoimmune diseases and restricting overwhelming immune-responses to pathogens 
are key tasks of these cells, which accounts for their original description as "suppressor 
T cells". They can be distinguished in naturally occurring (nTReg) and induced (iTReg) 
regulatory T cells. nTReg arise from the thymus, represent a stable cell lineage under 
steady state as well as inflammatory conditions and constantly undergo self-renewal in 
the periphery (Rubtsov, Niec et al. 2010). On the other hand, iTReg are generated in the 
periphery from TEff induced by cytokines like TGFß in immunosuppressive milieus and 
supplement the function of nTReg (Haribhai, Williams et al. 2011). Moreover, the presence 
of TReg is necessary throughout the lifespan of the host organism (Kim, Rasmussen et 
al. 2007). Immune suppression by TReg has been shown to use multiple major 
mechanisms (Vignali, Collison et al. 2008, Shevach 2009), which can be classified in 
non-contact- and contact-mediated suppression. An illustrative overview of the main 
regulatory T cell suppression mechanisms is provided in Figure 1.2. 
 
1.3.1 Non-contact-mediated regulatory T cell function  
One mechanism initially proposed is based on IL-2 consumption, a cytokine necessary 
in low amounts for homeostasis of all T cells and in high amounts for stimulation of clonal 
expansion. During the initial discovery of this cell lineage, the constitutive expression of 
the IL-2 receptor alpha-chain (CD25) on the cell surface and its function as a decoy 
receptor was described. However, this mechanism is disputed nowadays. Nevertheless, 
TReg significantly decrease IL-2 levels in vitro, most likely by inhibiting IL-2 mRNA 
induction in TEff (Thornton and Shevach 1998). 
 
Non-contact-mediated suppression mechanisms are based on the production of soluble 
factors by TReg and include the inhibitory cytokines IL-10, TGFß and IL-35. IL-10 is a 
cytokine known to contribute to TReg function, but is also produced by many other immune 
cells, like e.g. monocytes, mast cells and TH2 cells, and its deficiency preferentially 
affects autoimmune development in the gastrointestinal tract (Kuhn, Lohler et al. 1993). 
TGFß is a multi-functional cytokine that is expected to be mainly involved in TReg 
differentiation, rather than its suppressive function (Marie, Letterio et al. 2005, Shevach, 
Davidson et al. 2008). The cytokine IL-35 is contributing to TReg function by constitutive 
secretion and its suppressive effect on T cell proliferation. IL-35 has been proven to be 
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required in the immune control over inflammatory bowel diseases in vivo (Collison, 
Workman et al. 2007), however its absence could be compensated to prevent other 
autoimmune disorders. Therefore, IL-35 is not essential for TReg function. 
 
 
Figure 1.2: Overview of regulatory T cell suppression mechanisms 
[The figure is taken from a review by Vignali et al. 2008.] 
 
1.3.2 Contact-mediated regulatory T cell function 
Contact-mediated suppression mechanisms either function in contact with DCs by 
decreasing costimulation or in contact with TEff by cytolysis. Especially the  
contact-dependent decrease of costimulatory molecules CD80 and CD86 on DCs 
through the membrane protein CTLA-4 on TReg has been proven to be irreplaceable as 
mice with a conditional knock-out of CTLA-4 in Foxp3-expressing cells  
(i.e. CTLA-4-deficient TReg) suffer from fatal autoimmunity similar to overall Foxp3 
deficiency (Wing, Onishi et al. 2008). Likewise, mutations in the CTLA-4 gene in humans 
have been linked to complex immune dysregulation syndromes (Kuehn, Ouyang et al. 
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2014, Schubert, Bode et al. 2014). The decrease of CD80 and CD86 through CTLA-4 
can also be achieved by trans-endocytosis (Qureshi, Zheng et al. 2011). In this  
contact-dependent mechanism, the immune control by TReg indirectly suppresses TEff 
immune responses by decreasing the costimulation of DCs that are presenting  
self-antigen. Moreover, inactivated DCs sustain tolerance by rendering circulating  
self-reactive T cells anergic.  
 
1.4 Cell migration in adaptive immunity 
Cell migration is vital in the development and maintenance of multicellular organisms 
with implications in embryonic development, tissue repair and immune responses. 
Immune cell migration is as irreplaceable as the cells' effector function during 
homeostasis as well as during every stage of an adaptive immune response. As the 
adaptive immune system relies on the near infinite repertoire of T and B cells with each 
exhibiting a single specificity, a constant patrolling throughout the body is necessary for 
the recognition of antigens at any particular site. The critical interaction site of antigen, 
innate and adaptive immune cells is the lymph node. Cell migration involves a multitude 
of membrane and secretory protein families. For example, the extravasation of T 
lymphocytes from the blood stream into tissues, also referred to as transendothelial 
migration or diapedesis, involves cellular adhesion molecules (CAM) like selectins and 
integrins on the surfaces of endothelial cells and T lymphocytes, as well as cytokines 
capable of inducing chemotaxis, a mechanism of gradient-based guided cell migration.  
 
Chemokines and their receptors represent a protein family that is primarily responsible 
for chemotaxis and derived its name from the term chemotactic cytokines. They can be 
functionally divided into homeostatic and inflammatory chemokines. Homeostatic 
chemokines are constitutively produced and support steady state leukocyte patrolling. 
Inflammatory chemokines are induced by pro-inflammatory stimuli, like the cytokines 
interleukin-1 (IL-1) or tumor necrosis factor (TNF), and attract immune cells to the site of 
inflammation. Chemokines orchestrate systemic T cell migration in terms of cell homing 
to specific organs, as well as interstitial T cell migration in the sense of providing 
migratory pathways within lymphoid tissues. 
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1.4.1 Systemic T cell migration among lymphoid and non-lymphoid tissues 
During homeostasis, constant circulation of immune cells is provided via blood and 
lymphatic vessels. Naive T cells circulate through our body using the blood stream to 
lymph nodes and the efferent lymph via the thoracic duct back to the blood stream. This 
process is merely random but supported by constitutive production of the chemokines 
CCL19/21 by high endothelial venules (HEV), which supports lymph node entry of naive 
T cells based on their expression of the chemokine receptor CCR7 (Bromley, Mempel et 
al. 2008). In contrast, the circulation of memory T cells is sophistically orchestrated. 
Memory T cells can be divided in central memory T cells recirculating lymph nodes and 
effector memory T cells recirculating the organs of their generation, i.e. the organ in 
which the initial immune response took place. On the one hand, central memory T cells 
preserve their CCR7 expression to allow further circulation of lymph nodes. On the other 
hand, effector memory T cells are characterized by loss of CCR7 expression and 
acquisition of organ-specific chemokine receptor profiles, a feature provided by the 
interaction with DCs called imprinting (Mora, Bono et al. 2003). This important feature of 
cell migration is referred to as homing. For example, the recirculation of TEff to the skin 
is (among others) characterized by CCR4 expression, whereas recirculation to the gut is 
sustained (among others) by CCR9 expression.  
 
DCs, the antigen platform of lymph nodes, either transport antigens as peripheral DCs 
to the lymph node or take up lymph borne antigens as lymph node-resident local 
immature DCs (von Andrian and Mempel 2003). After peripheral DCs receive danger 
signals by a PAMP, they acquire expression of the chemokine receptor CCR7 in the 
process of maturation. This is an essential trigger for these DCs to enter afferent 
lymphatics and migrate to draining lymph nodes, guided by the homeostatic chemokine 
production of CCL19 and CCL21 by afferent lymph vessel endothelial cells (Forster, 
Schubel et al. 1999).  
 
Chemokines are also involved in the migration of TReg. Lymph node homing of TReg 
equally requires CCR7 expression, a property they share with TEff (Schneider, 
Meingassner et al. 2007). The chemokine receptor repertoire of TReg compared to TEff, 
however, appears to be more diverse, allowing different TReg subsets to home to a large 
variety of organs and sustain immune tolerance (Mailloux and Young 2010, Campbell 
2015). As a distinct difference, TReg show significantly higher expression of CCR4 and 
CCR8 along with stronger migratory response towards the respective chemokines 
Introduction 9 
 
 
CCL17/22 and CCL1 (Iellem 2001). An overview of chemokine receptor expression, 
migratory properties and implied function for TReg is provided in Table 1.1 (Campbell and 
Koch 2011). 
 
Receptor Site of migration Pathological implication 
   
CCR2 Inflamed tissues Allograft rejection 
CCR4 Skin Other inflamed tissues 
Skin and lung tolerance 
Inflammatory bowel disease 
Malignant tumor 
CCR5 Inflamed tissues 
Allograft rejection 
Leishmania infection 
Inflammatory bowel disease 
CCR6 TH17 cell-mediated inflammation TH17 cell-mediated  autoimmune diseases 
CCR7 Lymph node Spleen 
Inflammatory bowel disease 
Allograft rejection 
CCR8 Skin  TH2 cell-mediated inflammation Not yet characterized 
CCR9 Small intestine Not yet characterized 
CCR10 Mucosal tissues Skin 
Skin infection 
Inflamed liver 
Malignant tumor 
CXCR3 TH1 cell-mediated inflammation Inflamed liver 
CXCR4 Bone marrow Peyer's patches Malignant tumor 
CXCR6 Liver Not yet characterized 
Table 1.1: Overview of chemokine receptors expressed by regulatory T cells 
[The table is adapted from a review by Campbell and Koch, 2011] 
 
1.4.2 Interstitial T cell migration within lymphoid tissues 
The lymph node (LN) is a highly organized subunit of the immune system, integrating all 
available pieces of information for adaptive immune cells to make the fateful decision to 
either tolerate an antigen or launch an immune response against it. The interstitial 
migration of T cells within LNs is not stochastic but rather strategic to optimize the 
encounter with their cognate antigen (Krummel, Bartumeus et al. 2016). Microanatomic 
studies of LNs revealed specific distributions of immune cells in functionally separated 
areas, in particular T cell and B cell zones. This substructure in interstitial tissues 
depends on migration mechanisms – e.g. T cell zones show high CCL3 and CCL19 
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levels attracting CCR5+ and CCR7+ naive or central memory T cells, B cell zones show 
high CXCL13 levels attracting CXCR5+ B cells. The importance of these homeostatically 
produced chemokines in the functional organization of a lymph node is exemplified by 
various pathogens, like influenza virus, vaccinia virus and Listeria monocytogenes, 
which disrupt these interstitial migratory processes as an immune evasion mechanism 
to boost their pathogenicity (Mueller, Hosiawa-Meagher et al. 2007). A simplified 
illustration of lymph node homing and interstitial organization is provided in Figure 1.3.  
 
Figure 1.3: Basic illustration of lymph node homing and interstitial organization 
 
The T cell zone itself is a dynamic conglomerate of CD4+ effector (TEff) and CD8+ 
cytotoxic T lymphocytes (CTL), DCs and stroma cells. Specific guidance mechanisms 
are also essential to the function of this subunit, in particular if the interaction of three 
specialized subsets of immune cells is required.  
 
As an example, to initiate adaptive immune responses using TEff and CTL, both first need 
to interact with DCs. To facilitate these tricellular encounters, chemokines are induced 
during antigen-specific interaction of DCs and TEff to attract CTLs (Castellino, Huang et 
al. 2006), in this case CCL3, CCL4 and CCL5 for the chemokine receptor CCR5. This 
sophisticated mechanism could be identified in other functionally connected 
subpopulations of immune cells, e.g. DCs, TEff and NK cells (Semmling, Lukacs-Kornek 
et al. 2010), and highlights the importance of interstitial cell migration. 
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1.5 Objectives 
The main objective of this thesis was to investigate chemokine-based migration systems 
that could impact the interstitial interaction of DCs and TReg and thereby represent a 
potential mechanism involved in immune tolerance. As outlined in the chapters 1.1 to 
1.4, DCs integrate various pieces of information in the process of starting or inhibiting an 
immune response, such as the presence of pathogen-associated molecular patterns 
(PAMP) as a signal of danger for the host. The effectors of an adaptive immune response 
are T and B cells, which require the interaction with the dendritic cell as the central 
antigen-presenting platform of the host. As the interaction of DCs and TReg is necessary 
in the steady state to maintain immune tolerance (Wing, Onishi et al. 2008), a chemokine-
based migration system could be sustaining the interaction of these two cell types within 
the lymph node. Through comprehensive literature review and previous results of our 
research group, we hypothesize the CCL22-CCR4 axis to be involved in such a process. 
The chemokine CCL22 is homeostatically produced in large amounts by immature DCs 
(Vulcano, Albanesi et al. 2001), and known to be a ligand for the chemokine receptor 
CCR4 (Imai, Chantry et al. 1998). CCR4 is a chemokine receptor expressed by a variety 
of immune cells, with a very high expression as well as chemotactic response reported 
for TReg (Iellem 2001). Interestingly, CCR4 expression is driven by Foxp3, the 
transcriptional regulator of TReg (Yuan, Bromley et al. 2007). Therefore, I investigated the 
constitutively expressed chemokine CCL22 in DCs and the constitutively expressed 
CCL22-responding chemokine receptor CCR4 on TReg in interstitial migration of these 
cell types. Following questions were addressed: 
 
1. Do CCL22 and CCR4 play a role in cell-cell attraction of dendritic cells and 
regulatory T cells in vitro and in vivo? 
2. Do innate or adaptive immune responses influence the expression of CCL22 in 
dendritic cells and of CCR4 in regulatory T cells? 
3. Do CCL22 and CCR4 influence regulatory T cell suppression in vitro? 
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2 MATERIALS AND METHODS 
2.1 Materials 
2.1.1 Technical equipment 
Amaxa Nucleofector II Lonza, Basel, Switzerland 
Balance (LP 6209) Sartorius, Göttingen, Germany 
Cell culture CO2 incubator (BD 6220)  Heraeus, Hanau, Germany 
Cell culture laminar flow  Heraeus, Hanau, Germany 
Centrifuge 5417 R  Eppendorf, Hamburg, Germany 
Centrifuge 5424  Eppendorf, Hamburg, Germany 
Confocal Leica TCS SP5 Leica Microsystems, Wetzlar, Germany 
DynaMag 15/50 magnet  Invitrogen Dynal, Carlsbad, USA 
FACSCanto II  Becton Dickinson, San Jose, USA 
LightCycler 2.0 System  Roche, Mannheim, Germany 
Microscope Axiovert 25  Zeiss, Jena, Germany 
MiniMACS, QuadroMACS  Miltenyi, Bergisch Gladbach, Germany 
Mithras LB940 multilabel plate reader  Berthold, Bad Wildbad, Germany 
Multifuge 3L-R  Heraeus, Hanau, Germany 
Nanodrop ND-1000  NanoDrop, Wilmington, USA 
BX50WI fluorescence microscope Olympus, Tokyo, Japan 
Omnifuge 2 ORS  Heraeus, Hanau, Germany 
pH meter  WTW, Weilheim, Germany 
Power Supply 200/2.0  Biorad, Munich, Germany 
Refrigerators (4°C, -20°C, -80°C)  Thermo Scientific, Waltham, USA 
Shaker  NeoLab, Heidelberg, Germany 
Thermocycler T3  Biometra, Göttingen, Germany 
Thermomixer  Eppendorf, Hamburg, Germany 
Vortex VF2 Janke & Kunkel, Staufen, Germany 
 
2.1.2 Chemicals, reagents and buffers 
Aqua ad injectabilia  Braun AG, Melsungen, Germany 
Bovine serum albumine (BSA)  Sigma Aldrich, Steinheim, Germany 
Collagenase D  Roche, Mannheim, Germany 
Chloroform  Sigma Aldrich, Steinheim, Germany 
DNase II  Roche, Mannheim, Germany 
Dimethyl sulfoxide (DMSO) Sigma Aldrich, Steinheim, Germany 
Dulbecco’s PBS (1x)  PAA, Pasching, Austria 
Ethylenediaminetetraacetic acid (EDTA)  Sigma Aldrich, Steinheim, Germany 
FACSFlow, FACSSafe  Becton Dickinson, San Jose, USA 
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Heparin-Natrium 25,000 I.E./5 ml  Braun AG, Melsungen, Germany 
Isoflurane (Forene®)  Abbott, Zug, Switzerland 
Isopropanol (70 Vol%)  Apotheke Innenstadt, LMU Munich 
Paraformaldehyde (PFA)  Sigma Aldrich, Steinheim, Germany 
Sodium azide (NaN3)  Sigma Aldrich, Steinheim, Germany 
Sodium chloride (NaCl 0.9%)  Apotheke Innenstadt, LMU Munich 
Trypan blue  Sigma Aldrich, Steinheim, Germany 
Trypsin (10x) PAA, Pasching, Austria 
 
MACS buffer  Cell fixation buffer 
2 mM EDTA  2 % PFA 
2% FCS  in PBS 
in PBS 
 
ELISA coating buffer  ELISA assay diluent 
in PBS  10% FCS or 1% BSA 
pH 7.2-7.4 in PBS 
  pH 7.2-7.4 
 
ELISA wash buffer  
0.05% Tween 20  
in PBS 
 
2.1.3 Cell culture materials, reagents and media 
b-Mercaptoethanol  Sigma Aldrich, Steinheim, Germany 
5-Bromo-2′-deoxyuridine (BrdU) Sigma Aldrich, Steinheim, Germany 
DOTAP (N-[1-(2,3-Dioleoyloxy)propyl]- Roche, Mannheim, Germany 
3N-trimethylammonium-methylsulfate  
Dulbecco's modified Eagle ́s medium PAA, Pasching, Austria 
(DMEM), high glucose  
Fetal calf serum (FCS)  GibcoBRL, Karlsruhe, Germany 
Hank's balanced salt solution (HBSS)  PAA, Pasching, Austria 
Iscove's modified Dulbecco's medium PAA, Pasching, Austria 
(IMDM) 
L-glutamine 200mM  PAA, Pasching, Austria 
MEM-NEAA (non-essential amino acids)  GibcoBRL, Karlsruhe, Germany 
Phosphate-buffered saline (PBS)  PAA, Pasching, Austria 
Penicillin / streptomycin (100x)  PAA, Pasching, Austria 
Roswell Park Memorial Institute (RPMI) PAA, Pasching, Austria 
1640 medium  
Sodium pyruvate PAA, Pasching, Austria 
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RPMI complete medium  IMDM complete medium 
10% FCS 10% FCS 
2 mM L-glutamine  2 mM L-glutamine 
100 IU/ml penicillin  100 IU/ml penicillin 
100 μg/ml streptomycin  100 µg/ml streptomycin 
1 mM sodium pyruvate  1 mM sodium pyruvate 
1% non-essential amino acids  1% MEM-NEAA 
(MEM-NEAA)  in IMDM 
3.75 x 10-4 % b-mercaptoethanol  
in RPMI 1640 
 
DMEM complete medium  Cryo medium 
10% FCS 2 mM L-glutamine  50% DMEM complete medium 
100 IU/ml penicillin 40% FCS 
100 μg/ml streptomycin 10% DMSO 
 
Cytokines and OVA peptides  
Granulocyte-macrophage colony-stimulating PeproTech, Rocky Hill, USA 
factor (GM-CSF), recombinant murine 
IL-4, recombinant murine PeproTech, Rocky Hill, USA 
OVA 323-339 InvivoGen, San Diego, USA 
 
Chemokines and blocking antibodies 
Mouse CCL22 Antibody, monoclonal R&D Systems, Minneapolis, USA 
Recombinant Mouse CCL22 R&D Systems, Minneapolis, USA 
 
Disposable plastic materials for cell culture experiments were purchased from Becton 
Dickinson (Heidelberg, Germany), Bibby Sterilin (Stone, Staffordshire, Great Britain), 
Corning (Corning, USA), Eppendorf (Hamburg, Germany), Falcon (Heidelberg, 
Germany), Nunc (Rochester, USA) or Sarstedt (Nürnbrecht, Germany). 
 
2.1.4 Oligonucleotides, TLR ligands and other stimuli 
CpG 1826 (CpG)  Coley, Langenfeld, Germany 
Curdlan  Roche, Mannheim, Germany 
Flagellin  InvivoGen, San Diego, USA 
Lipopolysaccharide (LPS) Sigma, St. Louis, USA 
(Salmonella enterica ssp. enterica)  
PAM3CysSerLys4 (Pam3CysK)  tebu-bio, Offenbach, Germany 
Peptidoglycan InvivoGen, San Diego, USA 
Poly (dA) InvivoGen, San Diego, USA 
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Poly (I:C) HMW InvivoGen, San Diego, USA 
R848 InvivoGen, San Diego, USA 
ssPoly U Naked InvivoGen, San Diego, USA 
5’-triphosphate 2.2ds RNA (3pRNA) Eurogentec, Köln, Germany 
9.2s double right RNA CureVac, Tübingen, Germany 
 
Poly (dA), 3pRNA and Poly (I:C) HMW were transfected using Lipofectamine 2000 
Transfection Reagent (Thermo Fisher Scientific, Waltham, USA) according to the 
manufacturer’s instructions. 
 
2.1.5 Kits 
Cell labeling  
PKH26 Red Fluorescent Cell Linker Kit Sigma Aldrich, Steinheim, Germany 
PKH67 Red Fluorescent Cell Linker Kit Sigma Aldrich, Steinheim, Germany 
CellTracker Green CMFDA Dye Thermo Fisher Scientific, Waltham, USA 
CellTracker Orange CMTMR Dye Thermo Fisher Scientific, Waltham, USA 
 
RNA isolation, reverse transcription, qRT-PCR  
High pure RNA isolation kit  Roche, Mannheim, Germany 
Transcriptor first strand cDNA Roche, Mannheim, Germany 
synthesis kit   
LightCycler TaqMan Master kit  Roche, Mannheim, Germany 
Universal ProbeLibrary Roche, Mannheim, Germany 
 
Magnetic-activated cell sorting  
CD4+CD25+ T Cell Isolation Kit, murine Miltenyi, Bergisch Gladbach, Germany 
CD8a Micro Beads, murine  Miltenyi, Bergisch Gladbach, Germany 
CD11c Micro Beads, murine  Miltenyi, Bergisch Gladbach, Germany 
CD45R/B220 Micro Beads, murine Miltenyi, Bergisch Gladbach, Germany 
 
Cytokine ELISA sets  
CCL17 murine + human R&D Systems, Minneapolis, USA 
CCL22 murine + human R&D Systems, Minneapolis, USA 
IL-2 murine  BD Biosciences, San Diego, USA 
IL-10 murine  BD Biosciences, San Diego, USA 
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2.1.6 FACS antibodies 
Description Clone Distributor 
anti-BrdU BU20A BioLegend, San Diego, USA 
anti-CCR4 2G12 BioLegend, San Diego, USA 
anti-CD3 17A2 BioLegend, San Diego, USA 
anti-CD4 RMA4-5 BioLegend, San Diego, USA 
anti-CD8a 53-6.7 BioLegend, San Diego, USA 
anti-CD11c HL3 BioLegend, San Diego, USA 
anti-CD25 7D4 BioLegend, San Diego, USA 
anti-CD69 H1.2F3 BioLegend, San Diego, USA 
anti-CD80 16-10A1 BioLegend, San Diego, USA 
anti-CD86 GL1 BioLegend, San Diego, USA 
anti-Foxp3 FJK-16S eBioscience, San Diego, USA 
 
2.1.7 Software 
Adobe Illustrator CS4  Adobe System, San Jose, USA 
Endnote X7  Thompson Reuter, Carlsbad, USA 
FlowJo 8.7 Tree Star, Ashland, USA 
Imaris 7.0 Bitplane, Zurich, Switzerland 
Microsoft Office  Microsoft, Redmond, USA 
Prism 5 GraphPad, La Jolla, USA 
 
2.2 Methods 
2.2.1 Fluorescence-activated cell sorting (FACS) 
Fluorescent-activated cell sorting (FACS) - also called flow cytometry - is a method to 
count, investigate and sort cells. Single-cell suspensions need to be prepared for FACS 
analysis. A variety of antibodies conjugated with fluorescent molecules (fluorochromes) 
can be bound to an antigen. The cell suspension is taken up through a thin capillary into 
a flow cell, where the cells run through a focused laser beam one at a time. When hitting 
a cell, the light is either absorbed or scattered. Absorbed light of the appropriate 
wavelength will be re-emitted as fluorescence in case the cell has an attached 
fluorescent molecule or the cell is labeled with an antibody conjugated with a 
fluorochrome. The scatter of the light depends on intracellular structures and the cell's 
configuration and dimension. Light scatter at low angles depends on the relative cell 
dimension and is reported as forward scatter (FSC). Light scatter orthogonal to the 
capillary depends on the cell's granularity and surface configuration, which is recorded 
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as side scatter (SSC). Several photodiodes detect and amplify the fluorescence and light 
scatter. Optical filters permit light of a specific wavelength of fluorescence to reach the 
photodiode. 
In this thesis, all studies were performed with a FACSCanto II. This device used three 
lasers with a wavelength of 405 nm, 488 nm and 633 nm. A multi-color capability system 
detected the following fluorochromes: Pacific Blue, Pacific Orange, AmCyan, FITC, PE, 
PerCP, PerCP-Cy5.5, PE-Cy7, APC, APC-Cy7. 
 
2.2.1.1 Analysis of cell surface antigens 
For evaluation of antigens on the cell surface, the cells were diluted at 1-2 x 106 in PBS 
with 10% FCS. Up to seven flourochrome-conjugated antibodies targeted against 
antigens of interest were added at a 0.5 μl/ml concentration. Cells together with the 
antibodies were incubated for 30 minutes at a temperature of 4°C. During the staining, 
light exposure of cells was kept as low as possible. Cells were washed two times with 
PBS and re-suspended in PBS supplemented with 10% FCS for the FACS analysis.  
 
2.2.1.2 Analysis of intracellular antigens 
The intracellular transcription factor Foxp3 was analyzed to characterize regulatory T 
cells using the Treg staining Kit (BD Biosciences). At first, surface antigens were stained 
as described in the previous chapter. Antibodies bound to the cell surface were fixed and 
the cellular membranes were permeabilisized to enable the anti-Foxp3 antibody to enter 
the cytosol. For this, the cells were incubated in the fixation/permeabilisation buffer for 
30 minutes at a temperature of 4°C. After one washing step with buffer, the cells were 
incubated with 0.5 μl anti-Foxp3 antibody at a temperature of 4°C for another 30 minutes. 
At last, the cells were washed two times and suspended in PBS with 10% FCS for the 
following analysis. Furthermore, the intracellular uptake of BrdU was analyzed to 
measure the proliferation of cells. The staining with the anti-BrdU antibody was 
performed equal to anti-Foxp3. 
 
2.2.2 Magnetic-activated cell sorting (MACS) 
Magnetic-activated cell sorting (MACS) is a method to isolate live and functional cells 
with minimal interference for the following experiments. Cells are labeled with 
superparamagnetic particles, so-called magnetic beads. These are biodegradable, 
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therefore there is no need to remove them from the isolated cells after the sorting 
procedure. The magnetic beads are linked with antibodies specific for surface antigens 
of interest and attach to the cells expressing this specific antigen. Labeled cells are 
subsequently put into a plastic column that is placed in a strong magnetic field induced 
by a permanent magnet. The magnet retains cells attached to the magnetic beads in the 
column while unlabeled cells pass and are collected. After removing the column from the 
magnetic field, the retained cells can be washed out of the column and collected. 
Therefore, cells can be sorted positively or negatively. Positive selection is performed by 
isolating the cells of interest that are magnetically labeled and retained. Negative 
selection means depleting a cell suspension of unwanted cells and using the cell fraction 
passing through the magnet.  
 
In this thesis, all reagents were used from Miltenyi Biotec. TReg and TEff were isolated 
from splenocytes in a two-step process. In a first step, negative selection of CD4+ cells 
was performed by using an antibody cocktail against non-CD4+ cells. In a second step, 
positive selection using CD25 beads was performed. In line with the manufacturer’s 
instructions, cells were washed with MACS buffer and incubated together with the 
microbeads at a temperature of 4°C for 15 min and then washed two times. LD columns 
were rinsed with 3 ml MACS buffer, loaded with the incubated cells diluted in 2 ml of 
buffer and then positioned in the provided MACS separator magnet. The columns were 
washed in three steps with 3 ml MACS buffer. The effluent was collected as the negative 
fraction. After removal from the magnetic field, the elution was performed by using a 
plunger to flush the labeled cells of the column with 2 ml MACS buffer. For the smaller 
fractions of the CD4+ isolated cells MS columns were rinsed, loaded, washed two times 
and eluted with 1ml MACS buffer each. Splenic DCs were separated from splenocytes 
using CD11c beads and LD columns.  
 
2.2.3 Enzyme-linked immunosorbent assay (ELISA) 
The Enzyme-linked immunosorbent assay (ELISA) is a technique used to quantitatively 
analyze an antigen of interest in a sample by specific antibodies linked to enzymes. As 
an antibody binds to an antigen, this subsequently leads to the conversion of a substrate 
to a colored substance by the enzyme that is coupled to the antibody.  
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In this thesis, chemokines and cytokines from cell culture supernatants were analyzed 
by sandwich ELISA. ELISA detection plates were coated with antibodies that bind the 
desired antigen. Fixed antigens were treated with a second, biotinylated antibody. In a 
next step, this antibody was bound by streptavidin coupled with the enzyme peroxidase 
that catalyzes the oxidation of tetramethylbenzidine with hydrogen peroxide to a 
fluorescent molecule. The analysis of every studied antigen was done with openly 
available detection kits in line with the company’s' instructions. 
 
The detection plates were coated overnight at 4°C with capture antibody in coating 
buffer. Unspecific binding on the plates was minimized by diluent, applied for 60 minutes 
at room temperature. Coated plates were washed several times with washing buffer, 
then the samples and reference protein dilutions were put on the plates and again 
incubated. After several washing steps, horseradish peroxidase was used to identify the 
plate-bound detection antibody. After the incubation at room temperature, 
tetramethylbenzidine with hydrogen peroxide were used as substrates for the enzyme. 
For this, substrate solution was put into each well after the plates were washed. The 
enzymatic reaction was terminated by adding sulfuric acid. Readout of all ELISA assays 
was performed at 450 nm wavelength with correction through subtraction at 590 nm. 
 
2.2.4 Chemokine knock-down by RNA interference 
RNA interference (RNAi) is a technique that enables to modulate the expression of 
specific proteins by inhibiting the translation of the corresponding messenger RNA 
(mRNA). To achieve this, a specific RNA sequence is produced, e.g. in the form of  
short-interfering RNA (siRNA), that binds the corresponding mRNA. For this purpose, it 
has to be located in the cytosol to be in proximity to the mRNA. The binding of siRNA to 
the mRNA is mediated by the protein RNA-induced Silencing Complex (RISC), which 
subsequently leads to the cleavage and degradation of the mRNA. As a result, the mRNA 
cannot be translated and its corresponding protein not be produced. 
 
In this thesis, this method was used to inhibit the production of the chemokine CCL22 in 
bone marrow-derived dendritic cells (BMDC). BMDC from C57BL/6 mice were 
transfected (Amaxa nucleofector system; Y-001 immature DC program) at a cell number 
of 10 x 106 with 10 ng CCL22-siRNA (Mm_Ccl22_3 FlexiTube siRNA; Qiagen),  
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CCL17-siRNA (Mm_Ccl17_1 FlexiTube siRNA; Qiagen) or control-siRNA (AllStars 
Negative Control siRNA; Qiagen). After transfection DC were rested for 2 hours. 
 
2.2.5 T cell proliferation assay 
T cell proliferation was assessed by measuring the incorporation of  
5-Bromo-2′-deoxyuridine (BrdU) into the DNA of the cells during replication. Herefore, 
BrdU was added to the culture medium during the whole time of the incubation at a 
concentration of 10 µM. The BrdU uptake was assessed by flow cytometry analysis of 
intracellular BrdU (chapter 2.2.1.2.) using an anti-BrdU antibody (BioLegend).  
 
2.2.6 Reverse transcription polymerase chain reaction (RT-PCR) 
Total RNA was extracted from sorted single cell suspensions using High Pure RNA 
Isolation Kit (Qiagen) according to the manufacturer’s instructions. 1 µg of RNA was 
converted into cDNA using the Revert Aid First strand cDNA Synthesis Kit (Fermentas). 
Quantitative real-time PCR amplification was performed with the Light Cycler TaqMan 
Master (Roche Diagnostics) on a LightCycler 2.0 instrument (Roche Diagnostics) 
together with the Universal Probe Library System (Roche Diagnostics; CCL22 probe #84; 
HPRT probe #69). Relative gene expression is shown as a ratio of the CCL22 mRNA 
expression level to the expression level of hypoxanthine phosphoribosyltransferase 
(HPRT) mRNA. The primers for CCL22 (left: tcttgctgtggcaattcaga; right: 
gagggtgacggatgtagtcc) and HPRT (left: ggagcggtagcacctcct; right: 
ctggttcatcatcgctaatcac) were obtained from Metabion. 
 
2.2.7 Confocal microscopy 
In all experiments, static and dynamic visual data were achieved using a Leica TCS SP5 
laser-scanning confocal microscope (Leica Microsystems, Wetzlar, Germany). 
Magnification was set to 40x unless indicated otherwise. For general cell membrane 
labeling fluorophores PKH26 (Sigma, red dye) and PKH67 (Sigma, green dye) were used 
according to the manufacturer’s protocol. A xyz-positioning table enabled time-lapse 
video microscopy with intervals of 60 seconds unless indicated otherwise. In order to 
provide cell culture conditions during imaging, all samples were incubated at 37°C and 
5% CO2 using a heating stage (Leica, Microsystems, Wetzlar, Germany). 
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2.2.8 Cell lines and culture 
The murine immortalized DC line DC2.4 was kindly provided by K. Rock (University of 
Massachusetts, USA). DC2.4 and primary immune cells were cultured in RPMI1640 
medium supplemented with 10% FBS, 1% penicillin and streptomycin, 1% L-glutamine, 
1% sodium pyruvate, 1 mM HEPES and 50 µM β-mercaptoethanol (all from PAA). 
 
2.2.9 Statistical Analysis 
All data are presented as mean +/- SEM and the statistical significance of differences 
were determined by the two-tailed Student’s t-test. Statistical analyses were performed 
using GraphPad Prism 5 (GraphPad Software). p values < 0.05 were considered 
significant. 
 
2.3 Animal experimentation 
2.3.1 Animals 
Female C57BL/6 mice were purchased from Janvier Labs (Le Genest-Saint-Isle, 
France). Mice transgenic for a chicken OVA 323–339-specific T cell receptor (OT-II) were 
purchased from the Jackson laboratory (Bar Harbor, USA). OT-II-Foxp3-GFP mice were 
a gift from Vijay Kuchroo (Boston, USA). Mice were 5 to 10 weeks of age at the onset of 
experiments. Animal studies were approved by the local regulatory agency (Regierung 
von Oberbayern, Munich, Germany). 
 
2.3.2 Organ preparation 
2.3.2.1 Isolation of splenocytes and lymph node cells 
The mice were anesthetized with isoflurane and sacrificed. Spleens were removed and 
tissues were enzymatically digested with collagenase D (1 mg/ml) and DNase I  
(0.05 mg/ml) in complete medium at 37°C and moderate stirring for 25 to 35 minutes. 
The digested tissues were passed through a 40 μm-pore cell strainer to disintegrate 
tissue structure. Single cell solutions were washed with PBS and centrifuged at 400 G 
for 7 minutes and resuspended in erythrocyte lysis buffer. Red blood cell debris was 
removed by a second centrifugation step. Inguinal and axillary lymph nodes were 
resected and directly pressed through a 40 μm-pore cell strainer. 
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2.3.2.2 Generation of bone marrow-derived dendritic cells 
Bone marrow cells of wild type (WT) mice were isolated from the femur and tibia bones. 
After incubation with red blood lysis buffer cells were diluted to 1x106 cells/ml in RPMI 
medium supplemented with 10 % FBS (Gibco BRL), 1 % L-glutamine, 1 U/ml penicillin, 
0.1 mg/ml streptomycin (all PAA), 20 ng/ml GM-CSF and 20 ng/ml IL-4 (both 
PeproTech). Bone marrow-derived DCs (BMDC) were harvested on day 7. 
 
2.3.3 In vivo TLR stimulation assay 
Mice were injected subcutaneously with 100 µg fully phosphorothioated CpG 
oligodeoxynucleotide 1826 (59-TCCATGACGTTCCTGACGTT-39; Coley 
Pharmaceutical) diluted in 100 µl PBS or 100 µl PBS alone. Mice were sacrificed 24 
hours after injection. 
 
2.3.4 In vivo infection assay 
Mice were infected orally with the Salmonella enterica serovar Typhimurium (S. 
typhimurium) strain SB300. The strain was cultured in 0.3 M NaCl Luria–Bertani medium 
to allow for the activation of the Salmonella type III secretion system before oral infection. 
24 hours’ prior, mice were orally treated with 20 mg streptomycin to ensure consistent 
infection conditions. Water and food were withdrawn 4 hours before the mice were orally 
immunized with 103 colony forming units (CFU) of S. typhimurium in PBS by using round-
bottom gavage needles. Afterwards, drinking water was offered immediately and food 
was provided 2 hours later. Mice were sacrificed 24 hours after infection. 
 
2.3.5 Intravital microscopy 
Intravital microscopy is an umbrella term for the microscopic study of biological 
processes in vivo. In the field of immunology, the observation of leukocytes has long 
relied on ex vivo static analyses, which did not provide enough information about the 
physiologic movement of leukocytes. The research on the cell recruitment cascade was 
revolutionized by intravital microscopy. In these experiments, the blood vessels of mice 
were examined in paper-thin muscular structures, like e.g. the cremaster muscle, as this 
setup enables to visualize the blood vessels and the leukocytes by transillumination. 
This, however, limits the imaging studies to tissues with a maximum depth of 
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approximately 50 µm, thereby the study of secondary lymphoid organs such as the lymph 
node would not be possible by this technique. 
 
Multi-photon intravital imaging (MP-IVM) relies on the excitation of fluorophores by 
multiple uniform photons, which together meet the necessary energy, in contrast to a 
single high energy photon. In most applications, two uniform photons are generated by 
specialized pulsed lasers and used to excite the fluorophores. The wavelength is usually 
ranging in the infrared spectrum as this reduces the scattering significantly compared to 
photons of shorter wavelengths. The reduced scattering allows to excite fluorophores in 
deeper tissues of up to 1,000 µm. This technique therefore enabled us to study in vivo 
cell migration and interaction in secondary lymphoid tissues such as the lymph node. 
 
2.3.5.1 Animal preparation 
In the field of immunology, MP-IVM is often performed using the lymph node in the 
popliteal region of mice, as it lies superficial and is accessible for preparation. Prior to 
the preparation and during the whole imaging time period, the mice were anaesthetized 
by an injection of ketamine (50 mg/kg) and xylazine (10 mg/kg) into the peritoneum. The 
hair covering the right popliteal region was shaved off. The popliteal lymph node was 
prepared with microsurgical techniques, paying particular attention to not injure adjacent 
blood vessels or lymph vessels. The prepared lymph node was subsequently dipped in 
saline using a custom-built construction, which was covered by glass. This construction 
was connected to a thermocouple adjacent to the lymph node to maintain a temperature 
around 36 to 37°C. The right popliteal lymph node was then analyzed for 1 hour by  
two-photon intravital imaging on an Olympus BX50WI fluorescence microscope 
equipped with a 20×, 0.95 numerical aperture objective. 
 
In the experiments of this thesis, pretreated BMDC were used as experimental groups. 
The BMDC were prepared from bone marrow of C57BL/6 mice and transfected with 
either control- or CCL22-siRNA. Subsequently DC were pulsed with OVA323–339 
peptide and labeled for 20 min at 37°C with 10 mM 5-(and 6-)-([(4-chloromethyl)benzoyl] 
amino) tetramethylrhodamine (CellTracker CMTMR; Invitrogen) or  
7-amino-4-chloromethylcoumarin (Cell Tracker CMAC; Invitrogen). Control-siRNA- and 
CCL22-siRNA-treated DC (each at a number of 2x106) were co-injected in 20 µl IMDM 
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(with 10% FCS) containing 10 ng E. coli LPS (Sigma) into the right hind footpad of 
C57BL/6 OT-II-Foxp3-GFP mice.  
 
2.3.5.2 Data acquisition & analysis 
For four-dimensional analysis of cellular migration, stacks of six squared x–y sections 
with 6 µm z spacing were acquired every 20 s with electronic zooming up to 4 times to 
provide image volumes 30 µm in depth and 300 µm in width. All image analysis was 
performed blinded by two independent investigators using Imaris 7.0 software (Bitplane). 
Cells were manually tracked to calculate instantaneous velocities. The number of 
contacts and the contact time between DCs and TReg were manually measured. Cellular 
interactions that were shorter than 2 minutes or incompletely depicted spatially or 
temporally were excluded from the analysis. The contact time was manually measured 
in each case as number of frames during the interaction multiplied by the time interval of 
image acquisition.
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3 RESULTS 
 
Chemokine guidance of immune cells in interstitial tissues has been demonstrated to 
increase the interaction between distinct immune cell subgroups and amplify subsequent 
immune responses (Castellino, Huang et al. 2006, Semmling, Lukacs-Kornek et al. 
2010). We hypothesized that a chemokine-mediated mechanism may be involved in the 
formation of contacts between dendritic cells (DC), regulatory T cells (TReg) and effector 
T cells (TEff). Review of the literature and previous work of our research group identified 
the homeostatically produced chemokine CCL22 by DCs as a possible candidate, 
supported by the fact that the corresponding chemokine receptor CCR4 is highly 
expressed on TReg. This thesis investigates the in vitro and in vivo roles of CCL22 and 
CCR4 in interstitial migration of DCs and TReg, the regulation of CCL22 and CCR4 by 
innate and adaptive immunity and the role of CCL22 in in vitro TReg function. 
 
3.1 Static in vitro analysis of dendritic cell - regulatory T cell 
interaction 
In order to investigate whether the CCL22-CCR4 axis is involved in interstitial migration 
of DCs and TReg we studied static in vitro interactions of these cells in two independent 
experimental interaction setups as well as in the absence or presence of cognate antigen 
of TReg.  
 
3.1.1 CCL22 production favors antigen-independent dendritic cell - regulatory T cell 
interaction 
One method of studying in vitro cell interactions is coincubation of cells on  
fibrogen-coated flat bottom dishes, which allow 2-dimensional cellular migration. As a 
simplified model of chemokine-producing DCs we used the immortalized dendritic cell 
line DC2.4 (provided by K. Rock). This cell line is unable to secrete CCL22 due to the 
mutations leading to immortalization. As comparison, we used DC2.4 cells transfected 
with CCL22 (DC2.4-CCL22) that spontaneously and continuously produce CCL22. We 
set up a coincubation experiment of 100,000 MACS-sorted CD4+-CD25+ wild type (WT) 
TReg cells with either 50,000 DC2.4 or DC2.4-CCL22 cells on fibrogen-coated dishes. 
Prior to coincubation, the TReg cells and the DC2.4 cells were labeled using the 
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fluorophores PKH26 and PKH67. Colocalization analysis by confocal microscopy was 
used as readout after 15 and 30 hours of coincubation. Figure 3.1a shows the CCL22 
amounts in the supernatants of coincubated cells measured by ELISA, validating the 
CCL22 production of the transfected DC2.4 cell line. Figure 3.1b provides colocalization 
frequencies of TReg-DC per DC per high-power field that were measured by two 
independent blinded readers (representative of three independent experiments).  
 
Figure 3.1: Colocalization of coincubated TReg and immortalized DCs of the cell 
lines DC2.4 and DC2.4-CCL22 after 15 and 30 hours 
50,000 DC2.4 or DC2.4-CCL22 cells were coincubated with 100,000 CD4+-CD25+-sorted WT TReg 
and analyzed by confocal microscopy after 15 and 30 hours. (a) CCL22 levels were measured in 
the corresponding supernatants by ELISA. (b) The number of colocalized DC-TReg divided by all 
DCs in one high-power field (HPF) was assessed for 50 HPF in each condition. P values were 
calculated comparing DC2.4 and DC2.4-CCL22 (** p < 0.01; *** p < 0.001). 
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It shows that DC2.4-CCL22 have a significantly higher colocalization rate with TReg at the 
two different time points, 15 hours and 30 hours. Furthermore, the difference between 
the DC2.4 and DC2.4-CCL22 condition increased following longer coincubation time. 
These data suggest that CCL22 favors DC-TReg interactions in vitro in a time (or 
respectively dose)-dependent manner. 
 
3.1.2 CCL22 production favors antigen-dependent dendritic cell - regulatory T cell 
aggregate formation 
The formation of an immunological synapse between DCs and T cells is sustained by 
the presentation and recognition of cognate antigen and the interaction of costimulatory 
molecules. Onishi et al. investigated the setting in which TEff and TReg are competing for 
the interaction with a DC presenting their cognate antigen (Onishi, Fehervari et al. 2008). 
They demonstrated that DCs preferentially form aggregates with TReg, which therefore 
strongly outcompeted TEff. To study the role of CCL22 production by DCs in the process 
of DC - T cell aggregate formation in vitro we set up a coincubation experiment in round 
bottom dishes allowing 3-dimensional cellular interactions. An antigen-specific setting 
was established using T cells isolated from OT-II transgenic mice, which produce CD4+ 
T cells recognizing the specific peptide OVA 323-339 of the protein ovalbumin. 50,000 
MACS-sorted CD4+-CD25+ OT-II TReg cells together with 50,000 CD4+-CD25neg OT-II TEff 
and 25,000 MACS-sorted OVA 323-339 pulsed CD11c+ DCs were used. TReg and TEff 
cells were labeled prior to coincubation using the fluorophores PKH26 and PKH67. To 
study the presence and absence of CCL22, we added either anti-CCL22 blocking 
antibody or a control antibody at a concentration of 2 µg/ml. After 24 hours, the cells 
were gently transferred to glass bottom dishes to preserve the formed cell aggregates. 
Consecutively, the readout was performed using confocal microscopy and the contact 
ratio of TReg to TEff was measured per aggregate. The results of one of three independent 
experiments is shown in Figure 3.2a, representative confocal microscopy images are 
provided in Figure 3.2b. The TReg / TEff contact ratio is significantly lower in the condition 
with added anti-CCL22 blocking antibody compared to the control antibody. These data 
suggest that the absence of CCL22 decreases the likelihood of in vitro TReg aggregate 
formation with DCs compared to TEff and support the hypothesis that CCL22 promotes 
preferential encounters between DCs and TReg.  
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Figure 3.2: Contact ratio of OT-II TReg and OT-II TEff in antigen-dependent DC-T cell 
aggregate formation in the presence of control or anti-CCL22 blocking antibody 
25,000 OVA 323-339 pulsed CD11c+-sorted DCs were coincubated for 24 hours with 50,000 
CD4+-CD25+-sorted OT-II TReg and 50,000 CD4+-CD25neg-sorted OT-II TEff with control or  
anti-CCL22 blocking antibody (2 µg/ml) and subsequently gently transferred to glass bottom 
dishes for analysis by confocal microscopy. (a) The graph shows the ratio of OT-II TReg to OT-II 
TEff in DC-T cell aggregates. (b) Representative confocal microscopy images of DC-T cell 
aggregates for each condition. P value was calculated relative to the anti-CCL22 condition  
(** p < 0.01). 
 
Co
ntr
ol
An
ti-C
CL
22
0.0
0.5
1.0
1.5
2.0
2.5
3.0
3.5
**
T R
eg
/ T
Ef
f c
on
ta
ct
 ra
tio
 in
 D
C
-T
 c
el
l a
gg
re
ga
te
s
DC OT-II TEff OT-II TReg
Co
ntr
ol
An
ti-C
CL
22
a b
Results 29 
 
 
3.2 Dynamic in vivo analysis of dendritic cell - regulatory T cell 
interaction 
3.2.1 Experimental setup for in vivo analysis of the influence of CCL22 on  
dendritic cell - regulatory T cell interactions 
After establishing a role of CCL22 in static in vitro migration between DCs and TReg we 
wanted to investigate this hypothesis in vivo. Intravital microscopy of popliteal lymph 
nodes enables to visualize in vivo dynamic cell interactions. We set up an experiment 
using OT-II-Foxp3-GFP mice, in which OT-II TReg constitutively express a  
green-fluorescent protein. To track the movements of dendritic cells we injected  
ex vivo-labeled bone marrow-derived dendritic cells (BMDC) into the hind footpads of 
OT-II-Foxp3-GFP mice. In order to study the importance of CCL22 we used RNA 
interference to selectively downregulate the CCL22 production in one of two differently 
labeled coinjected groups of BMDC. To accomplish active homing of the injected BMDC 
to the draining lymph node we stimulated them by coinjection of the TLR4 ligand LPS. 
Figure 3.3 illustrates the experimental setup. 
 
Figure 3.3: Experimental setup for in vivo analysis of DC-TReg interactions and 
the influence of CCL22-CCR4-mediated attraction 
Intravital microscopy enables to study fluorescent cells in deep tissues like the T cell zones of 
lymph nodes. Regulatory T cells were detected by green-fluorescent protein (GFP) expression in 
OT-II-Foxp3-GFP mice. In order to study the influence of CCL22, bone marrow-derived dendritic 
cells were grouped and knock-down of CCL22 was performed. Subsequently the cells were 
labeled ex vivo with dyes developed for intravital microscopy and injected into the footpad. [The 
figure was partly taken from a review by (Fackler, Murooka et al. 2014) and adapted to the setup.] 
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3.2.2 CCL22 knock-down in dendritic cells and characterization of maturation status 
and lymph node homing 
We analyzed siControl- and siCCL22-treated BMDC in their immature state and after 
LPS-induced maturation for production of CCL22 and CCL17 by ELISA (Fig. 3.4a-b) and 
for expression of the maturation markers CD86 (Fig. 3.4c) and CD80 (not shown) by flow 
cytometry. Furthermore, we studied if the knock-down influences dendritic cell homing 
to the draining lymph node (Fig. 3.4d), as this could be a potential confounder in 
assessing DC-TReg interactions. The ELISA results confirm substantial decrease of the 
CCL22 production after siRNA knock-down. For maturation as well as lymph node 
homing we could show that there is no significant difference between the two groups of 
siControl- and siCCL22-treated BMDC as equal amounts of transferred BMDC were 
recovered from the draining lymph nodes.  
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Figure 3.4: CCL22 knock-down in BMDC and characterization of maturation status 
and lymph node homing 
(a-c) 4,000,000 BMDCs were either not treated or transfected with siControl, siCCL17, siCCL22 
or siCCL17 and siCCL22. Thereafter 200,000 BMDCs were incubated in the presence of absence 
of LPS (1 µg/ml) for 18 hours. Subsequently supernatants were analyzed by ELISA for CCL22 
levels (a) and CCL17 levels (b) and BMDCs were analyzed by flow cytometry for CD86 expression 
(c). (d/e) C57BL/6 WT mice (n=3) received 2,000,000 CMFDA-labeled siControl and 2,000,000 
CMTMR-labeled siCCL22 DC with 10 ng LPS in the right hind footpad. 18 hours later the right 
popliteal lymph node (draining LN) and the left popliteal lymph node (non-draining LN) were 
analyzed by flow cytometry. Error bars indicate SEM. P values were calculated relative to the 
siControl condition (*** p < 0.001). ns, not significant; nd, not detected. 
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3.2.3 CCL22 expression by dendritic cells influences interactions with regulatory T cells 
To study the in vivo interaction of DCs and TReg as well as the influence of CCL22 in an 
antigen-depending setting, siControl- and siCCL22-treated OVA 323-339 peptide pulsed 
BMDC were labeled with CMTMR or CMFDA and coinjected into the right hind footpad 
of OT-II-Foxp3-GFP mice. After 18 hours, the animals were prepared for intravital 
imaging: the mice were held under constant anesthesia by an initial intraperitoneal 
injection of ketamine (50 mg/kg) and xylazine (10 mg/kg), the skin in the popliteal region 
was exposed and the popliteal lymph node was dissected open and covered in a heating 
chamber at 37°C. Subsequently, intravital imaging was performed using a two-photon 
microscope for the duration of 1 hour (Fig. 3.5a). CMFDA-labeled siControl-treated DC 
were assigned the blue channel, CMTMR-labeled siCCL22-treated DC the red channel, 
and the GFP fluorescence of resident TReg the green channel. A representative in vivo 
image of the T cell zone of the popliteal lymph node is shown in Figure 3.5b. 
 
The acquired 4-dimensional image data were analyzed regarding instantaneous velocity 
of each cell group as well as contact time and frequency between either DC group and 
TReg. The instantaneous velocities of siControl- and siCCL22-treated DCs were 
calculated with automated software and were not significantly different but considerably 
slower than the velocity of TReg (Fig. 3.5c), a finding in line with previously published in 
vivo imaging studies (Matheu, Othy et al. 2015). No potentially confounding velocity 
difference was observed between the DC groups.  
 
The contact time and the contact frequency for TReg and siCCL22-treated DC compared 
to siControl-treated DC were manually and independently assessed by two blinded 
readers. The mean contact time for siCCL22-treated DC was significantly shorter (Fig. 
3.5d) and the mean contact frequency significantly lower (Fig. 3.5e). Taken together with 
the results from chapter 3.1, these data suggest an important role of the chemokine 
CCL22 in in vitro and in vivo cellular interactions between DCs and TReg during 
homeostasis as well as during antigen recognition. The results shown in Figure 3.5 
represent three independent experiments. 
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Figure 3.5: Intravital microscopy of cotransferred OVA 323-339 peptide-pulsed 
siControl and siCCL22 DC in the popliteal lymph node of OT-II-Foxp3-GFP mice 
(a) 2,000,000 CMFDA-labeled siControl and 2,000,000 CMTMR-labeled siCCL22 BMDC were 
pulsed with OVA 323-339 (1 µg/ml) for 1 hour and thereafter coinjected with 10 ng LPS in the 
right hind footpad of OT-II-Foxp3-GFP mice. The right popliteal lymph node was prepared and 
intravital microscopy was performed for 1 hour. (b) Representative image of the lymph node 
demonstrating the Foxp3-GFP signal (green) and the cotransferred siControl (blue) and siCCL22 
(red) DCs. (c) Instantaneous velocities of either population were measured using Bitplane Imaris 
software. (d) DC-OT-II TReg contact times were measured manually for siControl and siCCL22 
DCs. (e) Absolute numbers of OT-II TReg contacts with either DC population were measured over 
1 hour of imaging. P values were calculated relative to the siControl condition. ns, not significant. 
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3.3 Influence of the innate immune system on CCR4 expression 
Innate immunity plays a key role in host defense and the initiation of adaptive immunity. 
Since we established that the CCL22-CCR4 axis influences DC-TReg interactions in vitro 
and in vivo, we next wanted to examine how this chemokine-chemokine receptor axis 
responds during various stimulations of the innate immune system. Primarily we aimed 
to study the regulation of the chemokine receptor CCR4 expression, as previous work of 
our research group focused on the regulation of the chemokine CCL22. 
 
3.3.1 Regulation of CCR4 expression of regulatory T cells following stimulation of the 
innate immune system in vitro 
To investigate the influence of innate immune stimulation in vitro, we incubated 500,000 
WT splenocytes for 48 hours in the presence or absence of a variety of Toll-like receptor 
(TLR), RIG-I-like receptor (RLR) and Dectin-1 ligands, that are known as strong 
stimulators of innate immunity. Subsequently, we analyzed the CCR4 expression on TReg 
using flow cytometry (Fig. 3.6a, represents three independent experiments). The vast 
majority of stimuli led to a significant decrease of CCR4 expression on TReg, with the 
exception of the extracellularly applied TLR3 ligand poly (I:C) high molecular weight 
(HMW) and the TLR8 ligand poly U. On the other hand, transfection of the cells with poly 
(I:C) HMW, which is known to mainly interact with the intracellular receptor MDA5 of the 
RLR family, also led to a significant decrease of CCR4 expression. All in all, the data 
suggest that a multitude of innate immune stimuli lead to a downregulation of CCR4 
expression of TReg in vitro. 
 
3.3.2 Regulation of CCR4 expression of regulatory T cells following stimulation of the 
innate immune system in vivo 
Moreover, we studied the regulation of CCR4 expression in vivo by subcutaneous 
injection of 100 µg of the TLR9 ligand CpG (or PBS as control) in WT C57BL/6 mice. 
After 48 hours, spleen and lymph nodes were harvested and subsequently analyzed by 
flow cytometry for CCR4 expression of TReg. The mice treated with CpG showed a 
significantly decreased CCR4 expression on TReg compared to untreated mice (Fig. 3.6b, 
represents two independent experiments). In addition to stimulation with a purified TLR 
ligand we performed an oral infection assay with WT C57BL/6 mice using Salmonella 
typhimurium with subsequent flow cytometric analysis 24 hours later. Mice orally infected 
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with Salmonella typhimurium showed a significant decrease of CCR4 expression on TReg 
compared to untreated mice (Fig. 3.6c, represents two independent experiments). 
Altogether, these results suggest that CCR4 expression is downregulated following 
innate immune activation. 
 
Figure 3.6: CCR4 expression on TReg following pathogen-recognition receptor 
stimulation in vitro and in vivo and following S. typhimurium infection in vivo 
(a) 500,000 splenocytes of WT mice were incubated for 48 hours with TLR and RLR ligands and 
analyzed by flow cytometry for CCR4 expression on CD4+-Foxp3+ cells (TReg). Poly A control, 
3pRNA and poly (I:C) HMW on the far right were transfected. Error bars indicate SEM. P values 
were calculated relative to the untreated or in case of transfection to the poly A Control condition 
(* p < 0.05, ** p < 0.01, *** p < 0.001). ns, not significant. (b) C57BL/6 mice were injected 
subcutaneously with PBS (n=5) or 100 µg CpG (n=5). (c) C57BL/6 mice were infected orally with 
103 CFU of S. typhimurium (n=5) or untreated (n=5). 24 hours later splenocytes and lymph node 
cells were analyzed by flow cytometry for CCR4 expression on CD4+-Foxp3+ cells (TReg). P values 
were calculated relative to the untreated condition (* p < 0.05, ** p < 0.01, *** p < 0.001).  
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3.4 Influence of the adaptive immune system on CCL22 and 
CCR4 expression 
The DC exerts the pivotal role of presenting antigens to T and B cells, which it encounters 
in secondary lymphoid organs such as the lymph node. To promote these encounters, 
the DC makes use of chemokine-mediated migration involving proteins of the 
chemokine-chemokine-receptor family to attract its responder cells (Castellino, Huang et 
al. 2006, Semmling, Lukacs-Kornek et al. 2010). DCs interact with TEff and TReg and 
thereby stand at the crossroads of initiating or inhibiting an adaptive immune response. 
After studying the role of the innate immune system on CCL22 and CCR4 expression, 
we went on to investigate their regulation during an adaptive immune response. 
 
3.4.1 Increased CCL22 production by dendritic cells following T cell activation 
3.4.1.1 CCL22 production of splenocytes following T cell activation 
Since CCL22 is a chemokine produced by DCs, we wanted to study the dynamic effect 
of an antigen-specific immune response on its production. To answer this question, we 
incubated 500,000 splenocytes of OT-II TCR transgenic mice with the specific antigen 
OVA 323-339 at a concentration of 1 µg/ml for 12, 18, 24, 48 and 96 hours. 
Subsequently, the supernatants were collected and the amount of CCL22 was measured 
using ELISA. The OVA 323-339-treated conditions showed significantly higher levels of 
CCL22, even after only 12 hours of incubation (Fig. 3.7, represents three independent 
experiments). The strongest relative increase was observed after 24 hours with the OVA 
323-339-treated condition exceeding the untreated condition by more than 3-fold. A 
similar response was observed for the second CCR4 chemokine CCL17 (data not 
shown), whilst CCL17 concentrations were overall considerably lower. These results 
show that an adaptive immune response is associated with a strong and rapid induction 
of CCL22 production. 
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Figure 3.7: Kinetics of CCL22 production by OT-II splenocytes in the presence or 
absence of OVA 323-339 
500,000 OT-II splenocytes were incubated for 12, 18, 24, 48 and 96 hours in the presence or 
absence of the OT-II TCR specific antigen OVA 323-339 (1 µg/ml). CCL22 levels were measured 
by ELISA and are depicted as absolute values. Errors indicate SEM. P values were calculated 
relative to the untreated condition (* p < 0.05, ** p < 0.01, *** p < 0.001). ns, not significant; nd, 
not detected. 
 
3.4.1.2 CCL22 induction by T cell activation requires dendritic cells and T cells 
Since we identified that T cell activation increased CCL22 production in splenocytes, 
subsequently we wanted to verify if this effect takes place during interaction of DCs and 
TEff alone. Thus, we coincubated 25,000 MACS-sorted DCs and 50,000 CD4+-CD25neg 
T cells (TEff) of WT or OT-II transgenic mice for 48 hours with or without OVA 323-339 at 
a concentration of 1 µg/ml. Following coincubation, the supernatants were collected and 
CCL22 levels were measured using ELISA. The condition of DC and OT-II TEff showed 
a substantial increase in CCL22 production in the presence of cognate antigen (Fig. 3.8, 
represents four independent experiments). On the other hand, no significant difference 
was observed in the control condition with WT TEff. Previous results from our study group 
have shown that CCL22 in vitro is predominantly produced by DCs, but only if DCs are 
coincubated with T cells. Taken together, these results suggest that T cell activation 
through cognate antigen presented by DCs induces strong and rapid production of 
CCL22 by the antigen-presenting DC. 
0 h 12 h 18 h 24 h 48 h 96 h
0
2000
4000
6000
Untreated
OVA 323-339
*
**
***
*
ns
nd
C
C
L2
2 
(p
g/
m
l)
38 Results 
 
Figure 3.8: CCL22 levels of DCs and WT or OT-II TEff cells in the presence of  
OVA 323-339 
25,000 CD11c+-sorted DCs and 50,000 CD4+-CD25neg-sorted WT or OT-II TEff cells were 
incubated for 48 hours in the presence or absence of the OT-II TCR specific antigen  
OVA 323-339 (1 µg/ml). CCL22 levels were measured by ELISA. Error bars indicate SEM. P 
value was calculated relative to the untreated condition (*** p < 0.001). 
 
3.4.2 Increased CCR4 expression of regulatory T cells following T cell activation 
With the established induction of CCL22 production following T cell activation, we next 
wanted to study the effect of an antigen-specific immune response on CCR4 expression 
of TReg. To answer this question, we again tested murine splenocytes of OT-II TCR 
transgenic mice by initiating an adaptive T cell response with the specific antigen OVA 
323-339 in an experimental setup identical to the one in chapter 3.4.1.1. The cells were 
analyzed by flow cytometry after incubation for 48 hours. In OT-II splenocytes incubated 
with the cognate antigen OVA 323-339 showed a significant increase in CCR4 
expression on TReg but not TEff (Fig. 3.9, represents three independent experiments). No 
significant differences were observed for WT splenocytes. In addition, the results show 
that CCR4 expression is higher on naive TReg as compared to naive TEff. Taken together, 
these results show that antigen recognition by TReg is followed by an induction of their 
CCR4 expression. 
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Figure 3.9: CCR4 expression of WT or OT-II TEff and TReg cells in the presence of 
OVA323-339 
500,000 splenocytes of WT or OT-II mice were incubated for 48 hours in the presence or absence 
of the OT-II TCR specific antigen OVA 323-339 (1 µg/ml) and analyzed by flow cytometry. The 
CCR4 MFI was measured for CD4+-Foxp3neg cells (TEff) and CD4+-Foxp3+ cells (TReg). Error bars 
indicate SEM. P value was calculated relative to the untreated condition (*** p < 0.001). 
 
3.4.3 Differential regulation of CCL22 and CCR4 expression during combined 
activation of the innate and adaptive immune system 
Previous experiments by our research group and new experiments in this thesis showed 
that CCL22 and its receptor CCR4 are both downregulated by a variety of stimuli of the 
innate immune system, like e.g. the TLR9 ligand CpG, and upregulated during T cell 
activation. The next point we wanted to study was the combined influence of an innate 
and adaptive immune response on the expression of CCL22 and CCR4. Therefore, we 
incubated 500,000 OT-II splenocytes with combinations of the TLR9 ligand CpG  
(5 µg/ml) and / or the cognate antigen OVA 323-339 (1 µg/ml). The condition stimulated 
with CpG and OVA 323-339 still showed a decrease in CCL22 production compared to 
the untreated condition (Fig. 3.10a, represents three independent experiments). On the 
other hand, the CCR4 expression on TReg showed a moderate decrease but was still 
higher than in the untreated condition (Fig. 3.10b, represents three independent 
experiments). Therefore, the opposing effects of innate and adaptive immune activation 
are possibly different on CCL22 production and CCR4 expression. Nevertheless, we 
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conclude that the downregulation by the innate immune stimulation is partly abolished 
by the adaptive immune response. 
 
Figure 3.10: CCL22 production by OT-II splenocytes and CCR4 expression on 
OT-II TReg following TLR9 stimulation in the presence or absence of OVA 323-339 
500,000 OT-II splenocytes were incubated for 48 hours with the TLR9 ligand CpG (5 µg/ml) in the 
presence or absence of OVA 323-339 (1 µg/ml). Thereafter supernatants were analyzed for 
CCL22 levels (a) by ELISA and splenocytes for CCR4 expression (b) on CD4+-Foxp3+ cells (TReg) 
by flow cytometry. 
 
3.5 CCL22 expression by major dendritic cell subsets 
Different DC subsets are known to exert specific functions in innate and adaptive 
immunity, e.g. to induce innate antiviral immune responses or to present antigen on MHC 
I and II to corresponding T and B cells for adaptive immune responses. Therefore, we 
were interested to elaborate which subsets are responsible for the production of the 
chemokine CCL22 to further understand its role in immunity. We studied CCL22 
expression on the intracellular level by measuring the CCL22 mRNA levels in  
MACS-sorted DC subsets. As demonstrated in Figure 3.11, CD8a+ together with CD4+ 
myeloid DCs are expressing higher levels of CCL22 mRNA compared to B220+ 
plasmacytoid DCs. We could demonstrate the same differences on protein level by 
coincubation of these DC subsets with DC-depleted splenocytes by ELISA (data not 
shown). The CD8a+ and CD4+ myeloid DC subsets are known to be involved in T cell 
interaction, whereas B220+ plasmacytoid DC mainly function in innate antiviral immune 
responses. These data show that CCL22 is predominantly produced by DCs involved in 
T cell immunity.  
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Figure 3.11: CCL22 mRNA expression of DC subsets 
DC subsets were MACS-sorted from splenocytes of WT mice and their CCL22 mRNA expression 
was measured using RT-PCR. Errors indicate SEM. P values were calculated relative to the 
CD8a+ condition (** p < 0.01). 
 
3.6 Influence of CCL22 on suppression mechanisms of 
regulatory T cells in vitro 
TReg are known to make use of multiple mechanisms of immunosuppression, like e.g. 
inhibitory cytokines, suppression of DC function, metabolic disruption and cytolysis of TEff 
(Shevach 2009). In the previously described experiments, we investigated the impact of 
the CCL22-CCR4 axis on interactions of DCs and TReg in vitro and in vivo as well as its 
regulation during innate and adaptive immunity. The aim of the following experiments 
was to analyze the influence of CCL22 on TReg function in vitro.  
 
3.6.1 Regulatory T cell suppression of dendritic cell function in vitro 
One of the mechanisms of TReg-mediated immunosuppression on DCs is the 
downregulation of the costimulatory molecules CD80 and CD86 through  
trans-endocytosis of CTLA-4 (Wing, Onishi et al. 2008, Qureshi, Zheng et al. 2011). The 
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decreased expression of costimulatory molecules counteracts T cell activation and, in 
turn, can render TEff anergic. In order to study this in vitro, we set up a coculture 
experiment of 25,000 CD11c+-sorted DCs with or without 50,000 CD4+-CD25neg-sorted 
OT-II TEff or 50,000 CD4+-CD25+-sorted OT-II TReg in the presence or absence of OVA 
323-339 (1 µg/ml) for 48 hours. To investigate the influence of CCL22, we added  
anti-CCL22 blocking antibody (2 µg/ml) or recombinant CCL22 (1 µg/ml). After 48 hours 
of coincubation the cells were analyzed by flow cytometry for CD80 and CD86 
expression on DCs. The addition of OT-II TReg to the coculture significantly decreased 
CD80 and CD86 expression by DCs. Changing the concentration of CCL22 by  
anti-CCL22 blocking antibody or recombinant CCL22 did not affect CD80 or CD86 
expression (Fig. 3.12a-b, represents three independent experiments). The results do not 
support a role of CCL22 in in vitro suppression of costimulatory molecules. 
 
Figure 3.12: Antigen-dependent DC suppression assay by OT-II TReg at variable 
conditions of CCL22 
25,000 CD11c+-sorted DCs were coincubated for 48 hours as indicated with 50,000  
CD4+-CD25neg-sorted OT-II TEff, 50,000 CD4+-CD25+-sorted OT-II TReg, anti-CCL22 blocking 
antibody (2 µg/ml) or recombinant CCL22 (1 µg/ml) in the presence or absence of OVA 323-339 
(1 µg/ml) and subsequently analyzed by flow cytometry for CD80 (a) and CD86 (b) expression on 
dendritic cells. Error bars indicate SEM. P values were calculated relative to the DC + OT-II TEff 
condition (*** p < 0.001). ns, not significant. 
 
3.6.2 Regulatory T cell suppression of effector T cell function in vitro 
Aside from inhibiting the costimulatory capacity of DCs, the subsequent effect of  
TReg-mediated immunosuppression on TEff activation can be studied by assessing TEff 
proliferation and the expression of T cell activation markers. To study cell proliferation, 
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we used the same setup as in chapter 3.6.1 and added 5-bromo-2′-deoxyuridine (BrdU) 
to the coculture. BrdU is incorporated in dividing cells and was measured using flow 
cytometry. The addition of OT-II TReg significantly decreased OT-II TEff cell proliferation, 
but neither anti-CCL22 blocking antibody nor recombinant CCL22 altered the 
proliferation rate (Fig. 3.13a, represents three independent experiments). Furthermore, 
we analyzed the expression of the activation marker CD69 on OT-II TEff, which showed 
similar results (Fig. 3.13b, represents three independent experiments). These data do 
not support a role of CCL22 in in vitro suppression of TEff proliferation by TReg. 
 
 
Figure 3.13: OT-II TReg suppression in an antigen-dependent proliferation assay at 
variable conditions of CCL22 
25,000 CD11c+-sorted DCs were coincubated for 48 hours as indicated with 50,000  
CD4+-CD25neg-sorted OT-II TEff, 50,000 CD4+-CD25+-sorted OT-II TReg, anti-CCL22 blocking 
antibody (2 µg/ml) or recombinant CCL22 (1 µg/ml) in the presence or absence of OVA 323-339 
(1 µg/ml). BrdU was supplied in the cell culture medium. Cells were subsequently analyzed by 
flow cytometry for BrdU uptake in OT-II TEff (a) and CD69 expression on OT-II TEff (b). Error bars 
indicate SEM. P values were calculated relative to the DC + OT-II TEff condition (*** p < 0.001). 
ns, not significant. 
 
3.6.3 Regulatory T cell cytokine-mediated suppression in vitro 
Further mechanisms of TReg include IL-2 inhibition and production of inhibitory cytokines 
such as IL-10. The influence of CCL22 on these mechanisms was studied in vitro in the 
same experimental setup as in chapter 3.6.1 and 3.6.2, and protein levels were 
quantified using ELISA. In the presence of cognate antigen, OT-II TEff produced large 
amounts of IL-2. OT-II TReg significantly decreased IL-2 levels in the coculture and 
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produced IL-10 in the presence of the cognate antigen OVA 323-339. Neither adding 
anti-CCL22 blocking antibody nor recombinant CCL22 altered IL-2 production by OT-II 
TEff (Fig. 3.14a, represents three independent experiments) or IL-10 production by OT-II 
TReg (Fig. 3.14b, represents two independent experiments). 
 
Figure 3.14: IL-2 and IL-10 cytokine production in antigen-dependent suppression 
assays at variable conditions of CCL22 
25,000 CD11c+-sorted DCs were coincubated for 48 hours as indicated with 50,000  
CD4+-CD25neg-sorted OT-II TEff, 50,000 CD4+-CD25+-sorted OT-II TReg, anti-CCL22 blocking 
antibody (2 µg/ml) or recombinant CCL22 (1 µg/ml) in the presence or absence of OVA 323-339 
(1 µg/ml). Supernatants were analyzed for IL-2 (a) and IL-10 (b) levels by ELISA. Error bars 
indicate SEM. P value was calculated relative to the DC + OT-II TEff condition (*** p < 0.001). ns, 
not significant; nd, not detected. 
Taken together, no evidence supporting a function of CCL22 in in vitro TReg suppression 
could be found. However, these data can neither confirm nor exclude the function of 
CCL22 in in vivo adaptive immunity as the complexity of in vivo migration in interstitial 
tissues and cell interactions in secondary lymphoid organs cannot be adequately 
simulated in in vitro experiments. Therefore, in vivo studies are needed to investigate the 
role of CCL22 in immune tolerance. 
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4 DISCUSSION 
 
Our knowledge on immune tolerance has been largely expanded during the last five 
decades. Pioneering work was performed by Sir Frank Macfarlane Burnet, who 
introduced the scientific community to the distinction between self and non-self and 
received the Nobel Prize in Physiology or Medicine in the year 1960. Since then, immune 
tolerance has been further dissected into central, peripheral and dominant tolerance 
mechanisms, with the latter being investigated for only about two decades.  
 
Following the discovery of regulatory T cells (TReg), their important role in the 
pathogenesis of autoimmune diseases, in the management of organ transplantation as 
well as in immune evasion of malignant neoplasms soon became evident. These 
circumstances quickly made them a new promising target of immunotherapy. Efforts to 
increase or decrease TReg function depending on the pathological implication are 
successful, but then possibly accompanied by adverse effects like the onset of new 
autoimmune diseases. Therefore, understanding the exact mechanisms that balance the 
immune system are necessary. In this regard, targeting cell migration rather than cell 
function can be considered promising.  
 
Based on the present thesis, I will discuss the fundamental migratory mechanisms 
involved in interstitial interaction of dendritic cells (DCs) and T cells and review the 
relevance of specific chemokines and chemokine receptors for TReg function. Then I will 
summarize and integrate the new insights from the reported results of this thesis and 
provide an overview of already established and currently envisioned clinical applications 
in the context of cancer and autoimmune diseases. 
 
4.1 Interstitial migration in the interaction of dendritic cells and 
T cells within lymphoid and non-lymphoid tissues 
The interstitial migration of leukocytes in lymphoid tissues, in particular the lymph node, 
is a highly organized process. Among the many immune cell types that circulate the 
lymph nodes, DCs seek to interact with different subpopulations of T lymphocytes, which 
are all in constant search for their cognate antigen. The adaptive T cell response involves 
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not only CD4+ effector T cells (TEff) but also CD8+ cytotoxic T cells (CTL), which also 
need to find their cognate antigen first. Therefore, a tricellular encounter is required, 
which would at first sight be expected as unusual if not virtually impossible. To facilitate 
the interaction of all involved cells, a sophisticated mechanism has evolved. The cognate 
interaction of DCs and TEff induces the production of chemokines CCL3, CCL4 and CCL5 
in DCs, which subsequently attract CTLs to this specific DC (Castellino, Huang et al. 
2006). This whole mechanism takes place within a lymph node, and can therefore be 
attributed to interstitial migration. Interestingly, the aforementioned mechanism to 
facilitate tricellular interactions is not exclusive as a similar program was identified for 
DC, TEff and NK cells involving other chemokines (Semmling, Lukacs-Kornek et al. 2010). 
We hypothesized such a mechanism for the interstitial tricellular encounter of DC, TEff 
and TReg in lymph nodes. 
 
In in vitro experiments, we observed that the chemokine CCL22, produced by a modified 
immortalized dendritic cell line, attracted naive TReg and facilitated cell encounters in a 
dose-dependent manner. Furthermore, we used an experimental setup of splenic DCs, 
OT-II TEff and OT-II TReg, simulating the situation of tricellular encounters in the presence 
of cognate antigen. We could show that blocking CCL22 in the supernatant using 
neutralizing antibodies shifted the proportion of TEff to TReg in DC-T cell aggregates in the 
favor of TEff. Moreover, using an in vivo experiment based on intravital microscopy, we 
demonstrated a higher interaction frequency and longer interaction time of OT-II TReg 
with CCL22-producing DCs compared to CCL22-knock-down DCs in the setting of 
cognate antigen. Altogether, our results suggest a role of CCL22 in the interstitial 
interaction of DCs and TReg in homeostatic as well as inflammatory conditions. 
 
Our results provide further evidence that DC-TReg interactions are observed in vivo within 
lymph nodes. The very first study using intravital microscopy showed prolonged DC-TReg 
interactions, whereas stable contacts between TEff and TReg were not observed  (Tang, 
Adams et al. 2006), suggesting necessity of DC-TReg interactions for their in vivo function. 
Further insight was provided by an intravital microscopy study showing that the presence 
of TReg leads to an inhibition of stable DC-TEff interactions (Tadokoro, Shakhar et al. 
2006). DC-TReg interactions have also been shown in vivo in the tumor tissue (Bauer, 
Kim et al. 2014) as well as in adjacent tertiary lymphoid structures (Joshi, Akama-Garren 
et al. 2015). Recent data could show the importance of TReg in lymph nodes during 
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immune homeostasis, in which they continuously suppress populations of auto-reactive 
TEff in certain clusters, again in the proximity of DCs (Liu, Gerner et al. 2015).  
 
The impact of CCL22 to favor DC-TReg interactions observed in my experiments has to 
be put into context with previous studies. CCL22 has been shown to be upregulated in 
skin-resident DCs, also termed Langerhans cells, upon the initiation of DC maturation 
and subsequent lymph node homing (Tang and Cyster 1999). These CCL22-producing 
DC did not attract naive CD4+ T cells to the lymph node but rather already cognate 
antigen-exposed activated CD4+ T cells used in these experiments. This study, however, 
studied the homing of activated CD4+ T cells and did not investigate interstitial migration 
or positioning. A second study on this topic showed that CCL22 is specifically expressed 
by DCs in the T cell zones and showed in vitro chemotactic properties for activated T 
cells (Kanazawa, Nakamura et al. 1999). Both studies, however, did not distinguish the 
CD4+ T cell subpopulation in their experiments. In human peripheral blood mononuclear 
cells (PBMC), strong in vitro migration towards CCL22 was observed by activated  
TH2-CD4+ cells compared to TH1-CD4+ cells (Imai, Nagira et al. 1999). An ex vivo 
immunohistochemistry study in humans using inflamed skin and lymph nodes 
demonstrated that DC-T cell clusters showed CCL22 expression in DC and CCR4 
expression in T cells, not further specifying the T cell subpopulations involved (Katou, 
Ohtani et al. 2001).  
 
The only study so far to investigate the role of CCL22 in interstitial interactions of DC and 
TReg was performed in mesenteric lymph nodes (MLN) of mice (Onodera, Jang et al. 
2009). MLN-DCs were shown to constitutively produce indoleamine-2-3-dioxygenase 
(IDO), an enzyme generating an immunosuppressive environment due to the 
degradation and subsequent depletion of the essential amino acid tryptophan. 
Furthermore, certain subsets of MLN-DCs produced CCL22 as a response to apoptotic 
cells. The IDO production by MLN-DCs was shown to be significantly reduced in the 
presence of CTLA-4-deficient TReg as well as in CCR4-/- mice, suggesting a role of CCL22 
in DC-TReg interactions. Using static ex vivo immunohistochemistry of MLNs, however, 
no change in the frequency of colocalization of DC and TReg was reported when 
comparing wild type (WT) mice to CCR4-/- mice. The influence of CCR4 on the 
colocalization of DCs with TReg in the spleen or peripheral lymph nodes was not reported. 
Also, no studies of in vitro or in vivo interstitial migration were performed. Altogether, 
despite some previous evidence that CCL22 and CCR4 may interact to modulate TReg 
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function, our results are the first to show the impact of CCL22 on the interstitial interaction 
of DCs and TReg. 
 
4.2 Chemokines and chemokine receptors in regulatory T cell 
function 
Chemokines can affect cell function by controlling systemic migration in terms of homing 
to organs in which the cell needs to operate or in interstitial migration within lymphoid 
tissues to guide encounters with its functional cellular counterpart. In the following 
section, I will first discuss the known evidence regarding these differential influences for 
the chemokine CCL22 and its receptor CCR4. Based on that foundation, I will put our 
current and prior investigations of the regulation of CCL22 and its receptor CCR4 in 
different states of immune activation into context of the literature and the established 
CCL22-dependent interstitial interaction of DCs and TReg outlined in chapter 4.1. 
 
The chemokine CCL22 has been demonstrated to be involved in the homing of TReg in 
autoimmune disease models as well as in transplant tolerance. In an adoptive TEff cell 
transfer model of inflammatory bowel disease the co-transfer of TReg can prevent the 
resulting colitis. When using CCR4-/- TReg for co-transfer the inflammatory bowel disease 
developed similar to transfer of naive TEff alone (Yuan, Bromley et al. 2007). It was shown 
that CCR4-/- TReg failed to locate to mesenteric lymph nodes (MLN) in the early stages, 
whereas their numbers were increased relative to WT TReg in MLNs during the later 
stages of active and fully developed disease. Aside from homing, the authors also 
suggested that the decreased frequencies in MLNs could be caused due to ineffective 
retention of CCR4-/- TReg in MLNs, supposedly due to their inability to create contacts to 
MLN-DCs. This, however, was not further investigated by ex vivo immunohistochemistry 
or in vivo imaging.  
 
Concerning autoimmune disease models of type 1 diabetes using non-obese diabetic 
(NOD) mice, genetically engineered increased CCL22 production by endogenous islet 
cells as well as islet allografts conferred immune tolerance by increased homing of TReg 
to the pancreatic islets as well as lymph nodes of NOD mice (Montane, Bischoff et al. 
2011, Montane, Obach et al. 2015). Other studies also demonstrated a role of  
CCL22-producing myeloid DCs in TReg homing to pancreatic lymph nodes in the same 
model of type 1 diabetes (Layseca-Espinosa, Korniotis et al. 2013). Opposed to these 
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data, one study found CCR4+ TEff to be responsible for the clinical course of type 1 
diabetes in NOD mice (Kim, Cleary et al. 2002). Using adoptively transferred T cells from 
NOD mice into immunodeficient NOD-scid mice, in vivo neutralization of CCL22 resulted 
in decreased levels of insulitis as well as delayed onset of diabetes. These conflicting 
effects might probably be attributed to differential effects on TReg and TEff in a timely 
manner during the development of autoimmunity. 
 
Beyond the forecited models of induced autoimmune disease, the selective absence of 
CCR4 on TReg in steady state conditions also results in spontaneous autoimmune 
reactions in the skin and the lungs as well as peripheral lymphadenopathy in mice 
(Sather, Treuting et al. 2007). Concerning the dysfunction of CCR4-/- TReg in the skin and 
the lungs, the impaired homing of these cells could clearly be held responsible. The 
peripheral lymphadenopathy, however, again raised the hypothesis regarding efficient 
interactions with target cells facilitated by interstitial migration, as CCR4 is not essential 
for lymph node homing. Regarding skin tolerance, these findings were further supported 
by a skin disease model of the autoimmune disorder vitiligo, which depended significantly 
on CCL22 (Eby, Kang et al. 2015). For the complete picture it should be kept in mind, 
however, that CCR4 has been implied in memory T cell homing to the skin (Campbell, 
Haraldsen et al. 1999) and to the lung (Mikhak, Strassner et al. 2013) as well. 
 
With respect to transplant tolerance, the presence of CCR4 in TReg was essential for their 
homing to allografts in mouse models (Lee, Wang et al. 2005). In contrast, the further 
migration from allografts into draining lymph nodes was not affected by the absence of 
CCR4 on TReg (Zhang, Schroppel et al. 2009), but rather required the expression of 
CCR2, CCR5 and CCR7. These studies further support that CCR4 is dispensable for 
peripheral lymph node homing of TReg. The manifold implications of TReg migration and 
function, CCL22 and CCR4 in the setting of cancer will be discussed in further detail in 
chapter 4.3. 
 
In the next section, I will recapitulate the role of CCL22 integrating the above-mentioned 
evidence, prior investigations on differential CCL22 regulation from our research group 
and the new insights provided by the experiments of this thesis.  
The chemokine CCL22 is constitutively expressed in high amounts by immature DCs in 
lymph nodes (Kanazawa, Nakamura et al. 1999), but not by immature DCs in tissues like 
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the skin (Tang and Cyster 1999). Upon PAMP-induced maturation, DCs in the skin in 
vivo as well as isolated DCs in vitro show rapid upregulation of CCL22. In strong contrast 
to the skin, lymph-node resident DCs, however, show a rapid and strong downregulation 
of CCL22 in vivo in response to various PAMPs (unpublished observations). When 
culturing complete cells isolated from lymph nodes, this downregulation can also be 
observed in vitro, and was shown to be mediated by cytokines and to depend on the 
presence of T cells by our research group (unpublished observations). In this thesis, I 
further investigated the regulation of CCL22 production by DCs in cognate DC-TEff 
interactions in vitro and found a strong upregulation of CCL22 as early as 12 hours after 
antigen exposure and lasting for a period of 2 to 4 days. A similar regulation could be 
detected for its corresponding receptor CCR4 on TReg in vitro and in vivo. Using a 
multitude of in vitro experimental assays to assess the immunosuppressive function of 
TReg, I could not establish an impact of modulating CCL22 levels by recombinant CCL22 
or anti-CCL22 blocking antibodies. Studying chemokines in vitro, however, has obvious 
limitations, as the complex in vivo environment cannot be simulated appropriately.  
 
In the chain of reasoning, the experiment that would clarify the physiologic in vivo 
function of CCL22 and its receptor CCR4 in immune tolerance is the analysis of  
knock-out mice and their phenotype. Here, it should be considered that CCR4 also 
recognizes CCL17, so that only the knock-out of CCL22 would lead to unequivocal 
conclusions regarding the function of CCL22. The phenotype of CCL22-/- mice has not 
been previously studied. Therefore, our research group generated the CCL22-/- mouse. 
During homeostatic conditions, spontaneous immune dysregulations or autoimmune 
diseases were not detected in these mice (unpublished observations). However, 
following vaccination with Ovalbumine significantly stronger T and B cell responses were 
observed in CCL22-/- mice compared to WT mice. Moreover, the CCL22-/- mice were 
more severely affected in models of autoimmune disease like dextran sulfate sodium 
(DSS)-induced colitis compared to WT mice (unpublished observations).  
 
The proposed model for the function of CCL22 in immune tolerance during the steady 
state and during the inflammatory state, generated using data from this doctoral thesis, 
prior data from our research group and existing literature, is visualized in Figure 4.1.  
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Figure 4.1: Proposed model of CCL22-guided interstitial migration of regulatory T 
cells for immune tolerance in the steady state and in inflammatory conditions  
 
In the steady state, the constitutive CCL22 production by immature lymph node-resident 
DCs facilitates DC-TReg encounters to allow continuous screening for self-antigen in 
secondary lymphoid organs. Acute inflammation, however, almost completely reverses 
this setup: (1) immigrating DCs from peripheral tissues carrying antigens feature strongly 
induced CCL22 production, (2) lymph node-resident DCs exhibit strong reduction of 
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CCL22 production, whereas (3) lymph node-resident DCs in cognate antigen interactions 
with TEff preserve some CCL22 production despite inflammation. Collectively, this model 
suggests that TReg in this setting could easily identify, interact and if necessary control 
immigrating DCs as well as lymph node-resident DCs that are on the verge of T cell 
priming – both of which should be tightly observed to maintain immune tolerance in case 
of self-antigen presentation. 
 
4.3 Regulatory T cells and chemokines as targets of 
immunotherapy in cancer 
Cancer is one of the leading causes of mortality in the ageing societies of developed 
countries. The pathogenesis of malignant tumors is still a subject of intensive studies, 
and the search for targeted therapies to fight these devastating diseases ongoing. The 
vast majority of cancer therapies were and are still based on cytotoxic effects of 
chemotherapeutic agents. Tumor immunotherapy is an approach to modulate the 
patient's immune system in order to fight the cancer cells. William Bradley Coley is 
considered the pioneer of tumor immunotherapy. In the late 19th century, he made the 
observation that patients with infections after cancer surgery had a better prognosis, 
which motivated him to develop a mixture of killed bacteria termed Coley's toxin. Almost 
one century later, the Bacillus Calmette-Guérin (BCG) vaccine, an attenuated strain of 
Mycobacterium bovis, is used as the first-line therapy for non-invasive bladder cancer 
(Lamm, Blumenstein et al. 1991). Since then, many new ways of immunotherapy were 
discovered. In the recent decade, TReg have drawn attention as they accumulate in 
various types of cancer and are linked to poor clinical outcomes.  
 
The antitumor immune response is directed against multiple antigens of the tumor. These 
tumor-associated antigens have been shown to share properties with self-antigens 
rather than foreign antigens, and therefore antitumor immunity can in part be seen as a 
kind of autoimmunity (Nishikawa and Sakaguchi 2010). Accordingly, TReg could have a 
negative influence on antitumor immunity. In fact, this role for TReg was first verified by 
experiments using anti-CD25 antibody-mediated depletion of TReg, which resulted in the 
rejection of established tumors across a broad variety of tumor entities (Onizuka, Tawara 
et al. 1999, Shimizu, Yamazaki et al. 1999). In addition, TReg depletion can prevent the 
development of cancer in murine carcinogenesis models (Teng, Ngiow et al. 2010). 
Therefore, TReg display an interesting target in cancer therapy. 
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The very first study in the setting of human cancer reported a negative impact of 
increasing amounts of TReg in the tumor tissues on the survival of human ovarian cancer 
patients (Curiel, Coukos et al. 2004). The accumulation within the tumor was shown to 
be driven by CCL22. In the same tumor entity, another migratory mechanism involving 
CCL28 and CCR10-dependent migration of TReg could be identified (Facciabene, Peng 
et al. 2011), again with predictive value regarding the clinical course of the disease. In 
common cancer types with considerable socioeconomic influence like human colorectal 
cancer or human breast cancer, TReg also represent a serious risk factor for poor clinical 
outcome (Gobert, Treilleux et al. 2009, Deng, Zhang et al. 2010, Faget, Biota et al. 2011, 
Menetrier-Caux, Faget et al. 2012, Saito, Nishikawa et al. 2016).  
 
From a mechanistic point of view, the function of TReg in suppressing antitumor immunity 
was shown to be dependent on CTLA-4 expression (Wing, Onishi et al. 2008) and in vivo 
imaging of TReg function within tumors demonstrated local intratumoral DCs to be the 
cellular interaction counterpart (Bauer, Kim et al. 2014). Further evidence for the 
interaction between DCs and TReg in the context of cancer is provided by the functional 
involvement of TGFß (Chen, Pittet et al. 2005), IDO (Sharma, Baban et al. 2007), OX40 
(Piconese, Valzasina et al. 2008) and by perforin-dependent DC death exerted by TReg 
in tumor-draining lymph nodes (Boissonnas, Scholer-Dahirel et al. 2010), all of which 
were shown to depend on cognate antigen recognition.  
 
From a clinical point of view, the metastatic tumor burden is in general the life-limiting 
aspect of the disease. In this regard, TReg have been shown to favor lung metastases in 
breast cancer by homing mechanisms (Olkhanud, Baatar et al. 2009) and by  
TReg-produced receptor activator of nuclear factor-kB (RANK) ligand (RANKL), which was 
necessary for breast cancer cells to metastasize to the lung (Tan, Zhang et al. 2011). 
 
A medical breakthrough in the field of human tumor immunotherapy was the randomized 
clinical trial with ipilimumab, an antibody that targets CTLA-4. It showed improved 
survival in patients with metastatic melanoma (Hodi, O'Day et al. 2010). The increase in 
the median overall survival from 6.4 months to 10.0 months made ipilimumab the first 
drug to effectively improve the clinical course of metastatic melanoma and therefore 
ipilimumab was quickly established as the first-line therapy. Severe immune-related 
adverse events occurred in about 10% of patients, mainly including dermatologic, 
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gastrointestinal and endocrine adverse events. These were, however, reversible in most 
cases with immunosuppressive treatment. An elaborate analysis of the implication of 
CTLA-4 on TEff and TReg using compartmentalized expression of human CTLA-4 in mice 
suggested that the effect of anti-CTLA-4 treatment depends on blockade of CTLA-4 on 
TEff as well as on TReg (Peggs, Quezada et al. 2009). However, a later study identified 
the antibody-mediated Fc-dependent depletion of intratumoral TReg as the key 
mechanism underlying the clinical success of anti-CTLA-4 antibody immunotherapy 
(Simpson, Li et al. 2013). Newly developed antibodies such as nivolumab target other T 
cell molecules like the immune checkpoint inhibitor programmed cell death protein 1 (PD-
1), which however is mainly expressed on activated TEff rather than TReg. 
 
Aside from CTLA-4, other cell surface proteins of TReg have been extensively studied in 
preclinical settings in mice regarding their potential as targets of immunotherapy. OX40 
is a member of the family of costimulatory molecules and is constitutively expressed in 
murine TReg cells and transiently expressed in activated TEff. OX40 regulates the 
differentiation and clonal expansion of CD4+ TEff as well as activation of CTLs. In mice, 
OX40 agonists inhibit the development of tumors and are able to reject established 
tumors, both depending on the presence of TReg (Piconese, Valzasina et al. 2008). In 
humans, OX40 agonists have been tested in phase I clinical trials and represent a strong 
immune-stimulating agent with first positive clinical results in cancer patients (Curti, 
Kovacsovics-Bankowski et al. 2013).  
 
Another example of a costimulatory molecule on the cell surface of TReg, but also other 
CD4+ T cells, is the protein GITR (Glucocorticoid-Induced TNF-receptor family Related 
gene). Anti-GITR antibody treatment has been shown to inhibit TReg-mediated 
suppression, enhance TEff and CTL anti-tumor responses and lead to the eradication of 
established tumors (Ko, Yamazaki et al. 2005). The mechanism of GITR targeting plays 
an important role. Depleting antibodies likely lead to tumor rejection by TReg depletion 
(Kim, Shin et al. 2015). On the other hand, agonistic GITR antibodies were shown to 
modulate the differentiation of CD4+ T cells. The generation of induced TReg (iTReg) was 
inhibited, whereas the generation of TH9 cells was strongly enhanced, which contributed 
significantly to the anti-tumor immune response (Kim, Kim et al. 2015). 
 
Taken together, various approaches in antibody-mediated targeting of TReg have proven 
to be effective in murine and human cancer. For further drug development, new 
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strategies of combining established treatments as well as the screening of new cell 
surface markers that allow specific TReg targeting have great potential to contribute to the 
developing field of cancer immunotherapy. 
 
As the above-mentioned directly TReg-targeted immunotherapies are often accompanied 
by autoimmune side effects, altering the TReg migration to tumors through chemokines 
might be promising as an alternative target. Chemokines are a large family of proteins 
with multifaceted functions in innate and adaptive immunity. Here, I will focus on 
chemokines and chemokine receptors with TReg-related functions and their implications 
in cancer.  
 
TReg are recruited by solid malignancies as a means of immune escape and subsequent 
tumor progression. In particular, the amount of chemokines CCL22 for the receptor 
CCR4 and CCL28 for the receptor CCR10 were found to have high correlations with the 
amount of intratumoral TReg and most notably with the clinical outcome in human ovarian 
cancer patients (Curiel, Coukos et al. 2004, Facciabene, Peng et al. 2011). Among 
chemokines associated with TReg accumulation, CCL22 is so far the most studied 
chemokine. CCL22 is present in a variety of solid human tumors like breast cancer 
(Gobert, Treilleux et al. 2009), Hodgkin lymphoma (Ishida, Ishii et al. 2006), gastric 
adenocarcinoma (Mizukami, Kono et al. 2008), esophageal cancer (Maruyama, Kono et 
al. 2010) and in the malignant pleural effusion of lung cancer (Qin, Shi et al. 2009). In 
the studies investigating clinical implications, the CCL22 levels within the tumor 
correlated with the clinical progression of the disease. In the majority of cases, the main 
producers of the intratumoral CCL22 are identified as myeloid cells, in particular DCs. 
 
The suppression of intratumoral CCL22 production by Toll-like receptor (TLR) or  
RIG-I–like receptor (RLR) ligands leads to reduced TReg recruitment and lower numbers 
of intratumoral TReg (Anz, Rapp et al. 2015). In this activation of innate immunity, the 
main mediator of CCL22 suppression is interferon alpha (IFNa). Most notably, the  
well-established therapeutic effectiveness of TLR and RLR ligands was shown to depend 
on intratumoral CCL22 reduction. This could be proven by genetically modified  
CCL22-producing tumor cell lines, in which these therapies were ineffective. 
Not only the chemokine CCL22 but also its receptor CCR4 on TReg represents an 
interesting target of immunotherapy. Targeting CCR4 by small molecule antagonists acts 
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as a strong adjuvant in vaccination through decreased function of TReg (Bayry, Tchilian 
et al. 2008). The in vivo mechanism of these antagonists, however, was not elucidated. 
The combination of these CCR4 antagonists with vaccination against tumor antigens 
resulted in strong anti-tumor CTL responses and significantly reduced tumor growth 
(Pere, Montier et al. 2011). In the vaccine draining lymph node, decreased numbers of 
TReg were observed. It was, however, not further assessed whether this is due to 
decreased homing or decreased retention of TReg in this lymph node, which itself could 
be a result of decreased interstitial DC-TReg interactions.  
 
Opposed to CCR4 small molecule antagonists, an anti-CCR4 depleting antibody called 
mogamulizumab has been originally developed for treatment of adult T-cell leukemia. 
The reasoning was not based on direct targeting of TReg but rather depletion of leukemia 
cells, which were identified to strongly express CCR4. It soon emerged that CCR4 has 
actually two targets with the CCR4-expressing malignant cells as well as  
CCR4-expressing TReg and might exert a second effect in abolishing the TReg-mediated 
immune evasion (Ni, Jorgensen et al. 2015). Unfortunately, the associated TReg depletion 
also led to severe immune-related adverse events in some patients (Fuji, Inoue et al. 
2016), as was observed in anti-CTLA-4 antibody treatment. 
 
Interestingly, mogamulizumab also strongly amplified tumor antigen-specific immune 
responses in melanoma patients through the depletion of TReg (Sugiyama, Nishikawa et 
al. 2013), which suggested to expand the use of mogamulizumab on solid malignancies. 
In a recent phase I clinical trial of patients with lung cancer and esophageal cancer, 
Mogamulizumab also induced strong tumor antigen-specific T cell responses (Kurose, 
Ohue et al. 2015). The TReg depletion was highly efficient even at low doses and lasted 
for more than 6 months. These initial observations illustrate the potential of CCR4 as a 
target of immunotherapy and warrant further research in larger phase II clinical trials. In 
this context, our results represent an additional pathophysiologic explanation for the 
effectiveness of mogamulizumab and CCR4 small molecule antagonists. 
 
Last but not least, the function of CCR4 as a chemokine receptor that promotes DC 
interactions can also be exploited in adoptive T cell therapy (Rapp, Grassmann et al. 
2016). Modifying CTLs ex vivo to overexpress CCR4 proved to significantly enhance the 
efficacy of adoptive T cell therapy by directing CTLs to DCs, which resulted in increased 
CTL activation. 
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Taken together, TReg and the CCL22-CCR4 axis represent promising targets of 
immunotherapy in cancer. Initial feasibility in humans was already established for CCR4. 
CCL22 has so far not been studied in the human context in clinical trials. Yet in this 
setting, our data suggest that targeting the interaction of DCs and TReg by neutralizing 
CCL22 may be a promising alternative immunotherapy approach, as the severe  
immune-related adverse events resulting from TReg depletion in case of anti-CCR4 
antibody therapy could potentially be circumvented.  
 
4.4 Regulatory T cells and chemokines as targets of 
immunotherapy in autoimmune disease 
Autoimmunity can cause a heterogeneous group of diseases that manifest across all 
organs of the body that are surveilled by immune cells. The common ground for this 
disease entity is the reaction of the body's own immune system against self-antigens. 
The pathogenesis of many autoimmune diseases is under continuous investigation and 
the search for targeted therapies ongoing. The very first application of an immunotherapy 
in human autoimmune disease used cortisone in patients with rheumatoid arthritis and 
was performed 1948 by Philip Showalter Hench, who later received the Nobel Prize in 
Physiology or Medicine in 1950. In the recent decade, the crucial involvement of TReg in 
the development of different autoimmune diseases was discovered, making them an 
interesting therapeutic target. 
 
The dysfunction or the paucity of TReg within the affected organ represents one of many 
underlying pathophysiological mechanisms that disrupt the physiological immune 
balance (Buckner 2010). The various leukocytes that ultimately mediate the disease 
differ significantly between the specific autoimmune disorders and include innate as well 
as adaptive immune cells. Among the lymphocytes driving the disease are in particular 
the CD4+ TEff subpopulation with TH1 and TH17 differentiation (TH1 and TH17 cells), CTLs 
and B cells.  
 
In autoimmune diseases, the adoptive transfer of TReg can prevent disease onset in 
multiple murine models (Roncarolo and Battaglia 2007). However, the clinical goal in 
active autoimmune disease is to re-establish tolerance to the self-antigens involved in 
the specific autoimmune disorder (Sakaguchi, Powrie et al. 2012). Recent success was 
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achieved with the first phase I clinical trial of adoptive TReg transfer in patients with type 
1 diabetes (Bluestone, Buckner et al. 2015). Nevertheless, the major obstacle of adoptive 
TReg therapies is to reach cost-effective manufacturing and broad availability to be a 
viable therapeutic option (Trzonkowski, Bacchetta et al. 2015). 
 
As the presence of TReg in the specific organ can in general be considered favorable for 
the clinical outcome of the autoimmune disease, systemically altering the chemokines to 
direct migration of TReg does not represent a valuable therapeutic mechanism. However, 
localized application of chemokines like CCL22 is effective in skin autoimmune disorders 
such as vitiligo (Eby, Kang et al. 2015). Moreover, in the context of transplant tolerance 
as a cure for autoimmune diseases, reinforcing TReg migration to the allograft constitutes 
a reasonable approach. In the transplantation of islet cells in mouse models of type 1 
diabetes, the genetic modification of induced chemokine CCL22 expression by 
transplanted islet cells induces tolerance towards foreign antigens and promotes 
allograft survival (Montane, Obach et al. 2015). 
 
Besides adoptive TReg transfer, an approach to induce tolerance is to administer  
self-antigen-loaded DCs with tolerogenic properties to the patient, which is termed 
negative vaccination. My data show that modulating CCL22 secretion by DCs affects the 
interaction frequency with TEff and TReg. Furthermore, vaccination of CCL22-/- mice led to 
significantly stronger T cell responses compared to WT mice (unpublished observations). 
In accordance, increasing the chemokine receptor CCR4 expression of adoptively 
transferred T cells also resulted in stronger T cell responses through increased 
interaction with DCs (Rapp, Grassmann et al. 2016). These observations suggest that 
inducing CCL22 secretion of transferred DCs could potentially render them tolerogenic, 
whereas the inability to produce CCL22 leads to an increase in the DC's immunogenic 
potential. Taken together, increasing DC-TReg interactions through modulation of the 
CCL22-CCR4 axis may represent an alternative approach to balance the immune 
system towards a tolerogenic state in autoimmune diseases. 
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5 SUMMARY  
 
Immune tolerance by regulatory T cells (TReg) requires continuous interactions with 
dendritic cells (DCs) to screen the organism for potentially harmful self-antigen 
presentation. Ultimately, this interaction keeps effector T cells (TEff) with auto-reactive 
properties in check as the contact with DCs, TReg and cognate antigen induces anergy, 
a state of non-responsiveness. The efficient collaboration of these three immune cell 
types therefore dictates the delicate balance between immunity and tolerance. 
The aim of this study was to investigate the role of the chemokine CCL22 as a mediator 
of DC-TReg interactions. Based on previous observations of CCL22-dependent migration 
of CCR4+ TReg and CCL22 production by DCs, we hypothesized that CCL22 recruits TReg 
to DCs and increases their interaction frequency. Therefore, I investigated DC-TReg 
interactions in vitro and in vivo. In addition, I studied the influence of innate and adaptive 
immune stimulation on CCL22 and CCR4 expression. 
I showed that DC-TReg interactions were significantly more frequent in vitro and in vivo 
for DCs that secreted CCL22 compared to DCs that did not secrete CCL22. In vivo, I 
studied dynamic interactions in peripheral lymph nodes by intravital microscopy and 
observed longer antigen-dependent DC-TReg contact times for DCs that secreted CCL22. 
These results suggest that the homeostatic production of CCL22 by DCs serves as a 
signal to recruit TReg to support continuous immune tolerance during the steady state.  
Studying the influence of the innate immune system on the CCL22-CCR4 axis, I 
observed a decrease of CCR4 expression by TReg after stimulation with TLR and RLR 
ligands. In contrast, adaptive immune responses in the form of cognate-antigen DC-TEff 
interactions led to strong and rapid induction of CCR4 expression by TReg and further to 
CCL22 production by DCs. This strong induction following cognate-antigen interaction 
with TEff might represent a mechanism of immune surveillance, as more TReg will be 
recruited to the DCs that interact with TEff.  
These new mechanistic insights advance our comprehension of TReg function and may 
help to make use of their enormous potential in clinical applications for autoimmune 
diseases, for cancer and beyond.  
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Immunologische Toleranz durch regulatorische T-Zellen (TReg) beruht auf stetigen 
Interaktionen mit dendritischen Zellen (DCs), um die potenziell gefährliche Präsentation 
von Selbstantigenen im Organismus zu unterbinden. Diese Interaktion hält auto-reaktive 
T-Effektor-Zellen (TEff) unter Kontrolle, da der Kontakt mit DCs, TReg und dem passenden 
Antigen eine Anergie der DC und TEff erzeugt. Eine effiziente Zusammenarbeit dieser 
drei Immunzellen bestimmt somit die feine Balance zwischen Immunität und Toleranz. 
Ziel dieser Studie war es, die Rolle des Chemokins CCL22 als Mediator der  
DC-TReg-Interaktion zu untersuchen. Basierend auf früheren Beobachtungen der  
CCL22-abhängigen Migration von CCR4+ TReg und der CCL22-Produktion durch DCs, 
stellten wir die Hypothese auf, dass CCL22 TReg zu DCs migrieren lässt und die 
Häufigkeit der Interaktionen steigert. Darüber hinaus untersuchte ich den Einfluss der 
Stimulation des angeborenen und adaptiven Immunsystems auf die Expression von 
CCL22 und CCR4. 
Ich zeigte, dass DC-TReg-Interaktionen in vitro und in vivo signifikant häufiger sind, wenn 
DCs CCL22 sezernieren verglichen mit DCs, die dies nicht taten. In vivo untersuchte ich 
dynamische Interaktionen in peripheren Lymphknoten mittels intravitaler Mikroskopie 
und beobachtete längere DC-TReg Kontaktzeiten für DCs, die CCL22 sezernierten. Diese 
Ergebnisse deuten darauf hin, dass die homöostatische Produktion von CCL22 durch 
DCs als Signal zur Rekrutierung von TReg fungiert, um eine stete immunologische 
Toleranz im Ruhezustand zu gewährleisten. 
Bezüglich des Einflusses des angeborenen Immunsystems auf die CCL22-CCR4-
Achse, beobachtete ich eine Abnahme der CCR4-Expression bei TReg nach Stimulation 
mit TLR- und RLR-Liganden. Demgegenüber führten adaptive Immunantworten durch 
antigen-spezifische DC-TEff-Interaktion zu einer starken und schnellen Induktion der 
CCR4-Expression bei TReg und der CCL22-Produktion durch DCs. Dieser starke Anstieg 
nach einer antigen-spezifischen DC-TEff-Interaktion könnte ein Mechanismus der 
immunologischen Toleranz sein, um mehr TReg zu diesen DCs zu leiten, welche gerade 
mit TEff interagieren. 
Diese neuen mechanistischen Erkenntnisse verbessern unser Verständnis der Funktion 
von TReg und können dabei helfen, deren großes Potenzial in der klinisch-
therapeutischen Anwendung bei Autoimmun- und Krebserkrankungen zu nutzen.
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8 APPENDIX 
8.1 Abbreviations 
A 
a    Anti 
APC    Allophycocyanin 
APC    Antigen-presenting cell 
ATP    Adenosine triphosphate 
 
B 
BSA    Bovine serum albumin 
BMDC    Bone marrow-derived dendritic cells 
 
C 
CCL    CC chemokine ligand 
CCR    CC chemokine receptor 
CD    Cluster of differentiation 
CpG    Oligonucleotide with cytosine-(phosphate)-guanine motifs 
cpm    Counts per minute 
CTLA-4   Cytotoxic T lymphocyte antigen-4 
DC    Dendritic cell 
DMEM    Dulbecco’s modified Eagle’s medium 
DMSO    Dimethyl sulfoxide 
DNA    Desoxyribonucleid acid 
ds    Double-stranded 
 
E 
EDTA    Ethylenediaminetetraacetic acid 
ELISA    Enzyme-linked immunosorbent assay 
 
F 
FACS    Fluorescence-activated cell sorter 
FCS    Fetal calf serum 
FITC    Fluorescein isocyanate 
Foxp3    Forkhead box p3 
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FSC    Forward scatter 
 
G 
GM-CSF   Granulocyte-macrophage colony-stimulating factor 
HPF    High power field 
HPRT    Hypoxanthine-guanine phosphoribosyltransferase 
HRP    Horseradish peroxidase 
 
H 
HMW    High molecular weight 
 
I 
IBD    Inflammatory bowel disease 
IFN    Interferon 
Ig    Immunglobulin 
IL    Interleukin 
IVM    intravital microscopy 
 
L 
LFA-1    Lymphocyte function-associated antigen 1 
LN    Lymph node 
LPS    Lipopolysaccharide 
 
M 
mAb    Monoclonal antibody 
MACS    Magnetic-activated cell sorting 
MDA5    Melanoma differentiation-associated gene 5 
MDC    Macrophage-derived chemokine 
mDC    Mature dendritic cell 
MLN    Mesenteric lymph node 
MFI    Mean fluorescence intensity 
MHC    Major histocompatibility complex 
Min    Minute(s) 
Mio    Million(s) 
mRNA    Messenger RNA 
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MyD88   Myeloid differentiation factor 88 
MP-IVM   Multi-photon intravital microscopy 
 
N 
nd    Not determined 
NEAA    Non-essential amino acids 
ns    Not significant 
 
O 
ODN    Oligodesoxynucleotide 
OVA    Ovalbumine 
OVA 323-339   Ovalbumine peptide recognized by the T cell receptor of  
OT-II transgenic T cells 
OT-II    Derived from mice transgenic for a chicken OVA 323-339  
specific T cell receptor 
 
P 
PAMP    Pathogen-associated molecular pattern 
PBMC    Peripheral blood mononuclear cells 
PBS    Phosphate-buffered saline 
PCR    Polymerase chain reaction 
poly (dA:dT)   Poly (deoxyadenylic-deoxythymidylic) acid sodium salt 
pDC    Plasmacytoid dendritic cell 
PE    Phycoerythrin 
PerCP    Peridinin chlorophyll protein 
PFA    Paraformaldehyde 
PGN    Peptoglycans 
PHA    Phytohemagglutinine 
PI    Propidium iodide 
PLN    Peripheral lymph node 
PRR    Pattern recognition receptor 
PYD    Pyrin domain 
 
R 
RIG-I    Retinoic acid-inducible gene-I 
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RLR    RIG-I-like receptor 
RNA    Ribonucleic acid 
RPMI    Roswell Park Memorial Institute 
RT    Room temperature 
RT-PCR   Reverse transcription polymerase chain reaction 
 
S 
SEM    Standard error of mean 
SLO    Secondary lymphoid organs 
ss    Single-stranded 
SSC    Sideward scatter 
siRNA    Small interfering ribonucleic acid 
 
T 
TARC    Thymus- and activation-regulated chemokine 
TCR    T cell receptor 
TEff    CD4+-CD25neg-T-helper cell, effector T cell 
TLR    Toll-like receptor 
TMB    Tetramethylbenzidine 
TNF    Tumor necrosis factor 
TReg    CD4+-CD25+-Foxp3+-regulatory T cell 
 
V 
VLE    Very low endotoxin 
 
W 
WT    Wild type 
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